{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T13:51:55Z","timestamp":1783691515252,"version":"3.55.0"},"reference-count":321,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2016,7,1]],"date-time":"2016-07-01T00:00:00Z","timestamp":1467331200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["transplantationreviews.com","clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplantation Reviews"],"published-print":{"date-parts":[[2016,7]]},"DOI":"10.1016\/j.trre.2016.04.001","type":"journal-article","created":{"date-parts":[[2016,4,30]],"date-time":"2016-04-30T15:13:20Z","timestamp":1462029200000},"page":"119-143","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":109,"title":["Management of cytomegalovirus infection in solid organ transplant recipients: SET\/GESITRA-SEIMC\/REIPI recommendations"],"prefix":"10.1016","volume":"30","author":[{"given":"J.","family":"Torre-Cisneros","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.M.","family":"Aguado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.J.","family":"Caston","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Almenar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Alonso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Cantis\u00e1n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Carratal\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Cervera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Cordero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.C.","family":"Fari\u00f1as","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Fern\u00e1ndez-Ruiz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Fort\u00fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Frauca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Gavald\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Hern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"Herrero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"O.","family":"Len","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Lopez-Medrano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Manito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.A.","family":"Marcos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Mart\u00edn-D\u00e1vila","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Monforte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Montejo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Moreno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Mu\u00f1oz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Navarro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"P\u00e9rez-Romero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Rodriguez-Bernot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Rumbao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"San Juan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.M.","family":"Vaquero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Vidal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.trre.2016.04.001_bb0005","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1157\/13078802","article-title":"Consensus document from GESITRA-SEIMC on the prevention and treatment of cytomegalovirus infection in transplanted patients","volume":"23","author":"Torre-Cisneros","year":"2005","journal-title":"Enferm Infecc Microbiol Clin"},{"key":"10.1016\/j.trre.2016.04.001_bb0010","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/j.eimc.2011.05.022","article-title":"GESITRA-SEIMC\/REIPI recommendations for the management of cytomegalovirus infecion in solid-organ transplant patients","volume":"29","author":"Torre-Cisneros","year":"2011","journal-title":"Enferm Infecc Microbiol Clin"},{"key":"10.1016\/j.trre.2016.04.001_bb0015","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1097\/TP.0b013e31829df29d","article-title":"Updated international consensus guidelines on the management of cytomegalovirus in solid-organ transplantation","volume":"96","author":"Kotton","year":"2013","journal-title":"Transplantation"},{"key":"10.1016\/j.trre.2016.04.001_bb0020","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1136\/bmj.39500.677199.AE","article-title":"Grading quality of evidence and strength of recommendations for diagnostic tests and strategies","volume":"336","author":"Schunemann","year":"2008","journal-title":"BMJ"},{"key":"10.1016\/j.trre.2016.04.001_bb0025","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1136\/bmj.39504.506319.80","article-title":"Incorporating considerations of resources use into grading recommendations","volume":"336","author":"Guyatt","year":"2008","journal-title":"BMJ"},{"key":"10.1016\/j.trre.2016.04.001_bb0030","doi-asserted-by":"crossref","first-page":"a744","DOI":"10.1136\/bmj.a744","article-title":"Use of GRADE grid to reach decisions on clinical practice guidelines when consensus is elusive","volume":"337","author":"Jaeschke","year":"2008","journal-title":"BMJ"},{"key":"10.1016\/j.trre.2016.04.001_bb0035","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","article-title":"GRADE: an emerging consensus on rating quality of evidence and strength of recommendations","volume":"336","author":"Guyatt","year":"2008","journal-title":"BMJ"},{"key":"10.1016\/j.trre.2016.04.001_bb0040","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1111\/j.1537-2995.2008.01932.x","article-title":"Validation of an automated immunoglobulin G-only cytomegalovirus (CMV) antibody screening assay and an assessment of the risk of transfusion transmitted CMV from seronegative blood","volume":"49","author":"Seed","year":"2009","journal-title":"Transfusion"},{"key":"10.1016\/j.trre.2016.04.001_bb0045","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.jcv.2012.10.015","article-title":"Quantification of cytomegalovirus DNA by a fully automated real-time PCR for early diagnosis and monitoring of active viral infection in solid organ transplant recipients","volume":"56","author":"Boaretti","year":"2013","journal-title":"J Clin Virol"},{"key":"10.1016\/j.trre.2016.04.001_bb0050","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.jcv.2003.12.010","article-title":"Comparison of two quantitative CMV PCR tests, Cobas Amplicor CMV monitor and TaqMan assay, and pp65-antigenemia assay in the determination of viral loads from peripheral blood of organ transplant patients","volume":"30","author":"Piiparinen","year":"2004","journal-title":"J Clin Virol"},{"key":"10.1016\/j.trre.2016.04.001_bb0055","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.jcv.2008.03.031","article-title":"Relationship of cytomegalovirus load assessed by real-time PCR to pp65 antigenemia in organ transplant recipients","volume":"42","author":"Sanghavi","year":"2008","journal-title":"J Clin Virol"},{"key":"10.1016\/j.trre.2016.04.001_bb0060","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1128\/JCM.01499-07","article-title":"Prediction of cytomegalovirus (CMV) plasma load from evaluation of CMV whole-blood load in samples from renal transplant recipients","volume":"46","author":"Garrigue","year":"2008","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.trre.2016.04.001_bb0065","doi-asserted-by":"crossref","first-page":"87","DOI":"10.2353\/jmoldx.2009.080097","article-title":"Multi-site PCR-based CMV viral load assessment-assays demonstrate linearity and precision, but lack numeric standardization: a report of the association for molecular pathology","volume":"11","author":"Wolff","year":"2009","journal-title":"J Mol Diagn"},{"key":"10.1016\/j.trre.2016.04.001_bb0070","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1111\/j.1600-6143.2008.02513.x","article-title":"Interlaboratory comparison of cytomegalovirus viral load assays","volume":"9","author":"Pang","year":"2009","journal-title":"Am J Transplant"},{"key":"10.1016\/j.trre.2016.04.001_bb0075","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1128\/JCM.01287-11","article-title":"Factors contributing to variability of quantitative viral PCR results in proficiency testing samples: a multivariate analysis","volume":"50","author":"Hayden","year":"2012","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.trre.2016.04.001_bb0080","first-page":"1","article-title":"Coposed 1st WHO international standard for human cytomegalovirus for nucleic acid amplification-based assays","author":"Freyer","year":"2010","journal-title":"WHO\/BS\/10.2138, Geneva, Switzerland, 18\u201322 October 2010"},{"key":"10.1016\/j.trre.2016.04.001_bb0085","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1016\/S0140-6736(00)02350-3","article-title":"Application of viral-load kinetics to identify patients who develop cytomegalovirus disease after transplantation","volume":"355","author":"Emery","year":"2000","journal-title":"Lancet"},{"key":"10.1016\/j.trre.2016.04.001_bb0090","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1097\/00007890-199911150-00015","article-title":"Clinical utility of quantitative cytomegalovirus viral load determination for predicting cytomegalovirus disease in liver transplant recipients","volume":"68","author":"Humar","year":"1999","journal-title":"Transplantation"},{"key":"10.1016\/j.trre.2016.04.001_bb0095","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1128\/JCM.41.1.187-191.2003","article-title":"Measurement of human cytomegalovirus loads by quantitative real-time PCR for monitoring clinical intervention in transplant recipients","volume":"41","author":"Li","year":"2003","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.trre.2016.04.001_bb0100","doi-asserted-by":"crossref","first-page":"3757","DOI":"10.1128\/JCM.41.8.3757-3764.2003","article-title":"Monitoring of cytomegalovirus infection in solid-organ transplant recipients by an ultrasensitive plasma PCR assay","volume":"41","author":"Hadaya","year":"2003","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.trre.2016.04.001_bb0105","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1093\/cid\/cis900","article-title":"An international multicenter performance analysis of cytomegalovirus load tests","volume":"56","author":"Hirsch","year":"2013","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.trre.2016.04.001_bb0110","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.jcv.2012.09.017","article-title":"Determination, validation and standardization of a CMV DNA cut-off value in plasma for preemptive treatment of CMV infection in solid organ transplant recipients at lower risk for CMV infection","volume":"56","author":"Martin-Gandul","year":"2013","journal-title":"J Clin Virol"},{"key":"10.1016\/j.trre.2016.04.001_bb0115","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1093\/cid\/cit096","article-title":"Virologic suppression measured by a cytomegalovirus (CMV) DNA test calibrated to the World Health Organization international standard is predictive of CMV disease resolution in transplant recipients","volume":"56","author":"Razonable","year":"2013","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.trre.2016.04.001_bb0120","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1128\/CMR.00009-10","article-title":"Antiviral drug resistance of human cytomegalovirus","volume":"23","author":"Lurain","year":"2010","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.trre.2016.04.001_bb0125","doi-asserted-by":"crossref","DOI":"10.1038\/cti.2014.3","article-title":"Clinical immune-monitoring strategies for predicting infection risk in solid organ transplantation","volume":"3","author":"Fernandez-Ruiz","year":"2014","journal-title":"Clin Transl Immunol"},{"key":"10.1016\/j.trre.2016.04.001_bb0130","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1177\/135965350901400512","article-title":"Cytomegalovirus resistance in solid organ transplant recipients treated with intravenous ganciclovir or oral valganciclovir","volume":"14","author":"Boivin","year":"2009","journal-title":"Antivir Ther"},{"key":"10.1016\/j.trre.2016.04.001_bb0135","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.antiviral.2013.10.011","article-title":"Resistance of human cytomegalovirus to ganciclovir\/valganciclovir: a comprehensive review of putative resistance pathways","volume":"101","author":"Komatsu","year":"2014","journal-title":"Antiviral Res"},{"key":"10.1016\/j.trre.2016.04.001_bb0140","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1097\/QCO.0000000000000170","article-title":"Approach to drug-resistant cytomegalovirus in transplant recipients","volume":"28","author":"Chou","year":"2015","journal-title":"Curr Opin Infect Dis"},{"key":"10.1016\/j.trre.2016.04.001_bb0145","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/j.antiviral.2009.10.004","article-title":"A new tool linking human cytomegalovirus drug resistance mutations to resistance phenotypes","volume":"85","author":"Chevillotte","year":"2010","journal-title":"Antiviral Res"},{"key":"10.1016\/j.trre.2016.04.001_bb0150","doi-asserted-by":"crossref","first-page":"4697","DOI":"10.1128\/AAC.03214-14","article-title":"Improved detection of emerging drug-resistant mutant cytomegalovirus subpopulations by deep sequencing","volume":"58","author":"Chou","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.trre.2016.04.001_bb0155","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1093\/infdis\/jit654","article-title":"Phenotypic evaluation of previously uncharacterized cytomegalovirus DNA polymerase sequence variants detected in a valganciclovir treatment trial","volume":"209","author":"Chou","year":"2014","journal-title":"J Infect Dis"},{"key":"10.1016\/j.trre.2016.04.001_bb0160","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1097\/TP.0b013e31828ee12e","article-title":"International survey of cytomegalovirus management in solid organ transplantation after the publication of consensus guidelines","volume":"95","author":"Le Page","year":"2013","journal-title":"Transplantation"},{"key":"10.1016\/j.trre.2016.04.001_bb0165","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1016\/S0140-6736(05)66553-1","article-title":"Antiviral medications to prevent cytomegalovirus disease and early death in recipients of solid-organ transplants: a systematic review of randomised controlled trials","volume":"365","author":"Hodson","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.trre.2016.04.001_bb0170","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1086\/507337","article-title":"Preventing post-organ transplantation cytomegalovirus disease with ganciclovir: a meta-analysis comparing prophylactic and preemptive therapies","volume":"43","author":"Small","year":"2006","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.trre.2016.04.001_bb0175","doi-asserted-by":"crossref","first-page":"870","DOI":"10.7326\/0003-4819-143-12-200512200-00005","article-title":"Meta-analysis: the efficacy of strategies to prevent organ disease by cytomegalovirus in solid organ transplant recipients","volume":"143","author":"Kalil","year":"2005","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.trre.2016.04.001_bb0180","doi-asserted-by":"crossref","first-page":"2134","DOI":"10.1111\/j.1600-6143.2006.01413.x","article-title":"Prophylactic versus preemptive oral valganciclovir for the management of cytomegalovirus infection in adult renal transplant recipients","volume":"6","author":"Khoury","year":"2006","journal-title":"Am J Transplant"},{"key":"10.1016\/j.trre.2016.04.001_bb0185","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD005133.pub3","article-title":"Pre-emptive treatment for cytomegalovirus viraemia to prevent cytomegalovirus disease in solid organ transplant recipients","volume":"2","author":"Owers","year":"2013","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.trre.2016.04.001_bb0190","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1111\/j.1399-3062.2011.00652.x","article-title":"Preemptive versus prophylactic protocol to prevent cytomegalovirus infection after renal transplantation: a meta-analysis and systematic review of randomized controlled trials","volume":"13","author":"Zhang","year":"2011","journal-title":"Transpl Infect Dis"},{"key":"10.1016\/j.trre.2016.04.001_bb0195","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1093\/cid\/cit945","article-title":"A direct and indirect comparison meta-analysis on the efficacy of cytomegalovirus preventive strategies in solid organ transplant","volume":"58","author":"Florescu","year":"2014","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.trre.2016.04.001_bb0200","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1097\/01.tp.0000183970.71366.da","article-title":"Preemptive treatment for cytomegalovirus viremia to prevent cytomegalovirus disease in solid organ transplant recipients","volume":"81","author":"Strippoli","year":"2006","journal-title":"Transplantation"},{"key":"10.1016\/j.trre.2016.04.001_bb0205","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1111\/ajt.13044","article-title":"Universal prophylaxis or preemptive strategy for cytomegalovirus disease after liver transplantation: a systematic review and meta-analysis","volume":"15","author":"Mumtaz","year":"2015","journal-title":"Am J Transplant"},{"key":"10.1016\/j.trre.2016.04.001_bb0210","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1097\/01.TP.0000146844.65273.62","article-title":"Efficacy of valganciclovir administered as preemptive therapy for cytomegalovirus disease in liver transplant recipients: impact on viral load and late-onset cytomegalovirus disease","volume":"79","author":"Singh","year":"2005","journal-title":"Transplantation"},{"key":"10.1016\/j.trre.2016.04.001_bb0215","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1159\/000335962","article-title":"Pharmacoeconomic impact of different regimens to prevent cytomegalovirus infection in renal transplant recipients","volume":"35","author":"Kielberger","year":"2012","journal-title":"Kidney Blood Press Res"},{"key":"10.1016\/j.trre.2016.04.001_bb0220","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1002\/lt.23530","article-title":"Risk of cytomegalovirus disease in high-risk liver transplant recipients on valganciclovir prophylaxis: a systematic review and meta-analysis","volume":"18","author":"Kalil","year":"2012","journal-title":"Liver Transpl"},{"key":"10.1016\/j.trre.2016.04.001_bb0225","doi-asserted-by":"crossref","first-page":"260","DOI":"10.3947\/ic.2013.45.3.260","article-title":"Cytomegalovirus infections in solid organ transplantation: a review","volume":"45","author":"Ramanan","year":"2013","journal-title":"Infect Chemother"},{"key":"10.1016\/j.trre.2016.04.001_bb0230","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1002\/lt.23460","article-title":"Prophylaxis versus preemptive therapy for cytomegalovirus disease in high-risk liver transplant recipients","volume":"18","author":"Bodro","year":"2012","journal-title":"Liver Transpl"},{"key":"10.1016\/j.trre.2016.04.001_bb0235","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1002\/jmv.23539","article-title":"High risk of cytomegalovirus infection following solid organ transplantation despite prophylactic therapy","volume":"85","author":"Harvala","year":"2013","journal-title":"J Med Virol"},{"key":"10.1016\/j.trre.2016.04.001_bb0240","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.trre.2014.01.001","article-title":"The impact of the prevention strategies on the indirect effects of CMV infection in solid organ transplant recipients","volume":"28","author":"Roman","year":"2014","journal-title":"Transplant Rev"},{"key":"10.1016\/j.trre.2016.04.001_bb0245","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1038\/modpathol.3880032","article-title":"CMV and transplant-related coronary atherosclerosis: an immunohistochemical, in situ hybridization, and polymerase chain reaction in situ study","volume":"13","author":"Sambiase","year":"2000","journal-title":"Mod Pathol"},{"key":"10.1016\/j.trre.2016.04.001_bb0250","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1164\/ajrccm\/146.5_Pt_1.1213","article-title":"Ganciclovir prophylaxis for cytomegalovirus infections in pulmonary allograft recipients","volume":"146","author":"Duncan","year":"1992","journal-title":"Am Rev Respir Dis"},{"key":"10.1016\/j.trre.2016.04.001_bb0255","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1016\/j.healun.2009.03.012","article-title":"Cytomegalovirus prevention in high-risk lung transplant recipients: comparison of 3- vs 12-month valganciclovir therapy","volume":"28","author":"Jaksch","year":"2009","journal-title":"J Heart Lung Transplant"},{"key":"10.1016\/j.trre.2016.04.001_bb0260","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1097\/00007890-199504270-00012","article-title":"Efficacy of a 6-week prophylactic ganciclovir regimen and the role of serial cytomegalovirus antibody testing in lung transplant recipients","volume":"59","author":"Kelly","year":"1995","journal-title":"Transplantation"},{"key":"10.1016\/j.trre.2016.04.001_bb0265","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1016\/S1053-2498(02)00648-4","article-title":"Impact of prophylaxis with cytogam alone on the incidence of CMV viremia in CMV-seropositive lung transplant recipients","volume":"22","author":"Kruger","year":"2003","journal-title":"J Heart Lung Transplant"},{"key":"10.1016\/j.trre.2016.04.001_bb0270","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1046\/j.1399-0012.2003.00152.x","article-title":"Delay of CMV infection in high-risk CMV mismatch lung transplant recipients due to prophylaxis with oral ganciclovir","volume":"18","author":"Palmer","year":"2004","journal-title":"Clin Transpl"},{"key":"10.1016\/j.trre.2016.04.001_bb0275","doi-asserted-by":"crossref","first-page":"761","DOI":"10.7326\/0003-4819-152-12-201006150-00003","article-title":"Extended valganciclovir prophylaxis to prevent cytomegalovirus after lung transplantation: a randomized, controlled trial","volume":"152","author":"Palmer","year":"2010","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.trre.2016.04.001_bb0280","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1034\/j.1600-6143.2003.00074.x","article-title":"Combination prophylaxis with ganciclovir and cytomegalovirus (CMV) immune globulin after lung transplantation: effective CMV prevention following daclizumab induction","volume":"3","author":"Weill","year":"2003","journal-title":"Am J Transplant"},{"key":"10.1016\/j.trre.2016.04.001_bb0285","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1111\/j.1399-3062.2009.00416.x","article-title":"Preemptive therapy is not adequate for prevention of cytomegalovirus disease in pancreas-kidney transplant recipients","volume":"11","author":"Lopez-Medrano","year":"2009","journal-title":"Transpl Infect Dis"},{"key":"10.1016\/j.trre.2016.04.001_bb0290","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/j.transproceed.2004.03.002","article-title":"Efficacy and limitations of preemptive therapy against cytomegalovirus infections in heart transplant patients","volume":"36","author":"Casillo","year":"2004","journal-title":"Transplant Proc"},{"key":"10.1016\/j.trre.2016.04.001_bb0295","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1097\/00007890-199803150-00026","article-title":"Preemptive treatment for the prevention of cytomegalovirus disease: in lung and heart transplant recipients","volume":"65","author":"Egan","year":"1998","journal-title":"Transplantation"},{"key":"10.1016\/j.trre.2016.04.001_bb0300","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1111\/j.1432-2277.2007.00526.x","article-title":"Long-term outcome of cytomegalovirus infection in simultaneous pancreas-kidney transplant recipients without ganciclovir prophylaxis","volume":"20","author":"Rayes","year":"2007","journal-title":"Transpl Int"},{"key":"10.1016\/j.trre.2016.04.001_bb0305","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1002\/lt.22431","article-title":"Epidemiology and outcome of infections in human immunodeficiency virus\/hepatitis C virus-coinfected liver transplant recipients: a FIPSE\/GESIDA prospective cohort study","volume":"18","author":"Moreno","year":"2012","journal-title":"Liver Transpl"},{"key":"10.1016\/j.trre.2016.04.001_bb0310","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1056\/NEJM198905253202105","article-title":"A randomized, placebo-controlled trial of oral acyclovir for the prevention of cytomegalovirus disease in recipients of renal allografts","volume":"320","author":"Balfour","year":"1989","journal-title":"N Engl J Med"},{"key":"10.1016\/j.trre.2016.04.001_bb0315","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1056\/NEJM199905133401903","article-title":"Valacyclovir for the prevention of cytomegalovirus disease after renal transplantation. International Valacyclovir cytomegalovirus prophylaxis transplantation study group","volume":"340","author":"Lowance","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1016\/j.trre.2016.04.001_bb0320","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1111\/j.1600-6143.2007.02133.x","article-title":"Improvement in long-term renal graft survival due to CMV prophylaxis with oral ganciclovir: results of a randomized clinical trial","volume":"8","author":"Kliem","year":"2008","journal-title":"Am J Transplant"},{"key":"10.1016\/j.trre.2016.04.001_bb0325","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1111\/j.1600-6143.2004.00382.x","article-title":"Efficacy and safety of valganciclovir vs. oral ganciclovir for prevention of cytomegalovirus disease in solid organ transplant recipients","volume":"4","author":"Paya","year":"2004","journal-title":"Am J Transplant"},{"key":"10.1016\/j.trre.2016.04.001_bb0330","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1111\/j.1600-6143.2010.03074.x","article-title":"The efficacy and safety of 200days valganciclovir cytomegalovirus prophylaxis in high-risk kidney transplant recipients","volume":"10","author":"Humar","year":"2010","journal-title":"Am J Transplant"},{"key":"10.1016\/j.trre.2016.04.001_bb0335","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1111\/j.1600-6143.2010.03342.x","article-title":"IMPACT trial results should not change current standard of care of 100days for cytomegalovirus prophylaxis","volume":"11","author":"Kalil","year":"2011","journal-title":"Am J Transplant"},{"key":"10.1016\/j.trre.2016.04.001_bb0340","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1111\/j.1600-6143.2010.03370.x","article-title":"Response to questions regarding the design and results of the IMPACT trial","volume":"11","author":"Humar","year":"2011","journal-title":"Am J Transplant"},{"key":"10.1016\/j.trre.2016.04.001_bb0345","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1111\/j.1399-3062.2000.020303.x","article-title":"Prevention of primary cytomegalovirus disease in organ transplant recipients with oral ganciclovir or oral acyclovir prophylaxis","volume":"2","author":"Rubin","year":"2000","journal-title":"Transpl Infect Dis"},{"key":"10.1016\/j.trre.2016.04.001_bb0350","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1097\/01.TP.0000040601.60276.96","article-title":"Randomized controlled trial of oral ganciclovir versus oral acyclovir after induction with intravenous ganciclovir for long-term prophylaxis of cytomegalovirus disease in cytomegalovirus-seropositive liver transplant recipients","volume":"75","author":"Winston","year":"2003","journal-title":"Transplantation"},{"key":"10.1016\/j.trre.2016.04.001_bb0355","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD003774.pub4","article-title":"Antiviral medications for preventing cytomegalovirus disease in solid organ transplant recipients","volume":"2","author":"Hodson","year":"2013","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.trre.2016.04.001_bb0360","first-page":"669","article-title":"Efficacy and safety of universal valganciclovir prophylaxis combined with a tacrolimus\/mycophenolate-based regimen in kidney transplantation","volume":"137","author":"Manuel","year":"2007","journal-title":"Swiss Med Wkly"},{"key":"10.1016\/j.trre.2016.04.001_bb0365","doi-asserted-by":"crossref","first-page":"18","DOI":"10.7326\/0003-4819-123-1-199507010-00002","article-title":"Preemptive ganciclovir therapy to prevent cytomegalovirus disease in cytomegalovirus antibody-positive renal transplant recipients. A randomized controlled trial","volume":"123","author":"Hibberd","year":"1995","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.trre.2016.04.001_bb0370","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1097\/01.tp.0000225830.76907.d0","article-title":"Valganciclovir preemptive therapy for the prevention of cytomegalovirus disease in high-risk seropositive solid-organ transplant recipients","volume":"82","author":"Diaz-Pedroche","year":"2006","journal-title":"Transplantation"},{"key":"10.1016\/j.trre.2016.04.001_bb0375","doi-asserted-by":"crossref","first-page":"294","DOI":"10.2215\/CJN.07020714","article-title":"Randomized trial of valganciclovir versus valacyclovir prophylaxis for prevention of cytomegalovirus in renal transplantation","volume":"10","author":"Reischig","year":"2015","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.trre.2016.04.001_bb0380","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1034\/j.1399-3062.1999.010202.x","article-title":"High-dose acyclovir prophylaxis reduces cytomegalovirus disease in liver transplant patients","volume":"1","author":"Barkholt","year":"1999","journal-title":"Transpl Infect Dis"},{"key":"10.1016\/j.trre.2016.04.001_bb0385","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1016\/S0140-6736(97)05535-9","article-title":"Randomised trial of efficacy and safety of oral ganciclovir in the prevention of cytomegalovirus disease in liver-transplant recipients. The oral ganciclovir international transplantation study group [corrected]","volume":"350","author":"Gane","year":"1997","journal-title":"Lancet"},{"key":"10.1016\/j.trre.2016.04.001_bb0390","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1097\/01.TP.0000093463.86584.AC","volume":"77","author":"Winston","year":"2004","journal-title":"Transplantation"},{"key":"10.1016\/j.trre.2016.04.001_bb0395","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0005512","article-title":"Valganciclovir for cytomegalovirus prevention in solid organ transplant patients: an evidence-based reassessment of safety and efficacy","volume":"4","author":"Kalil","year":"2009","journal-title":"PLoS One"},{"key":"10.1016\/j.trre.2016.04.001_bb0400","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1002\/lt.21769","article-title":"Increased incidence of cytomegalovirus infection in high-risk liver transplant recipients receiving valganciclovir prophylaxis versus ganciclovir prophylaxis","volume":"15","author":"Shiley","year":"2009","journal-title":"Liver Transpl"},{"key":"10.1016\/j.trre.2016.04.001_bb0405","doi-asserted-by":"crossref","first-page":"2189","DOI":"10.1016\/j.transproceed.2009.06.005","article-title":"Prophylactic therapy with valgancyclovir in high-risk (cytomegalovirus D+\/R\u2212) liver transplant recipients: a single-center experience","volume":"41","author":"Montejo","year":"2009","journal-title":"Transplant Proc"},{"key":"10.1016\/j.trre.2016.04.001_bb0410","doi-asserted-by":"crossref","first-page":"3021","DOI":"10.1111\/j.1600-6143.2012.04231.x","article-title":"Efficacy and safety of maribavir dosed at 100mg orally twice daily for the prevention of cytomegalovirus disease in liver transplant recipients: a randomized, double-blind, multicenter controlled trial","volume":"12","author":"Winston","year":"2012","journal-title":"Am J Transplant"},{"key":"10.1016\/j.trre.2016.04.001_bb0415","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1016\/j.transproceed.2013.01.082","article-title":"Maribavir use in practice for cytomegalovirus infection in French transplantation centers","volume":"45","author":"Alain","year":"2013","journal-title":"Transplant Proc"},{"key":"10.1016\/j.trre.2016.04.001_bb0420","first-page":"32","article-title":"A double-blind placebo-controlled trial of low-dose ganciclovir to prevent cytomegalovirus disease after heart transplantation","volume":"14","author":"Macdonald","year":"1995","journal-title":"J Heart Lung Transplant"},{"key":"10.1016\/j.trre.2016.04.001_bb0425","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1056\/NEJM199204303261803","article-title":"A controlled trial of ganciclovir to prevent cytomegalovirus disease after heart transplantation","volume":"326","author":"Merigan","year":"1992","journal-title":"N Engl J Med"},{"key":"10.1016\/j.trre.2016.04.001_bb0430","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1128\/AAC.39.7.1643","article-title":"Prospective randomized trial of efficacy of ganciclovir versus that of anti-cytomegalovirus (CMV) immunoglobulin to prevent CMV disease in CMV-seropositive heart transplant recipients treated with OKT3","volume":"39","author":"Aguado","year":"1995","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.trre.2016.04.001_bb0435","first-page":"659","article-title":"Combined antiviral and immunoglobulin therapy as prophylaxis against cytomegalovirus infection after heart transplantation","volume":"14","author":"Valenza","year":"1995","journal-title":"J Heart Lung Transplant"},{"key":"10.1016\/j.trre.2016.04.001_bb0440","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1097\/00007890-200111270-00012","article-title":"Impact of cytomegalovirus hyperimmune globulin on outcome after cardiothoracic transplantation: a comparative study of combined prophylaxis with CMV hyperimmune globulin plus ganciclovir versus ganciclovir alone","volume":"72","author":"Valantine","year":"2001","journal-title":"Transplantation"},{"key":"10.1016\/j.trre.2016.04.001_bb0445","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1097\/01.TP.0000119722.37337.DC","article-title":"Comparison of combined prophylaxis of cytomegalovirus hyperimmune globulin plus ganciclovir versus cytomegalovirus hyperimmune globulin alone in high-risk heart transplant recipients","volume":"77","author":"Bonaros","year":"2004","journal-title":"Transplantation"},{"key":"10.1016\/j.trre.2016.04.001_bb0450","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.healun.2009.08.018","article-title":"Changing trends in infectious disease in heart transplantation","volume":"29","author":"Haddad","year":"2010","journal-title":"J Heart Lung Transplant"},{"key":"10.1016\/j.trre.2016.04.001_bb0455","doi-asserted-by":"crossref","first-page":"2228","DOI":"10.1016\/j.transproceed.2007.07.039","article-title":"Impact of valganciclovir prophylaxis on the development of severe late-cytomegalovirus disease in high-risk solid organ transplant recipients","volume":"39","author":"Cervera","year":"2007","journal-title":"Transplant Proc"},{"key":"10.1016\/j.trre.2016.04.001_bb0460","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1111\/j.1399-3062.2009.00450.x","article-title":"Comparison of higher dose and lower dose ganciclovir for cytomegalovirus prophylaxis in seropositive heart transplant recipients","volume":"12","author":"Lee","year":"2010","journal-title":"Transpl Infect Dis"},{"key":"10.1016\/j.trre.2016.04.001_bb0465","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1378\/chest.116.5.1265","article-title":"Costs and outcomes of prolonged cytomegalovirus prophylaxis to cover the enhanced immunosuppression phase following lung transplantation","volume":"116","author":"Gerbase","year":"1999","journal-title":"Chest"},{"key":"10.1016\/j.trre.2016.04.001_bb0470","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1164\/ajrccm.150.1.8025741","article-title":"A comparison of ganciclovir and acyclovir to prevent cytomegalovirus after lung transplantation","volume":"150","author":"Duncan","year":"1994","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.trre.2016.04.001_bb0475","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1111\/j.1600-6143.2004.00571.x","article-title":"Following universal prophylaxis with intravenous ganciclovir and cytomegalovirus immune globulin, valganciclovir is safe and effective for prevention of CMV infection following lung transplantation","volume":"4","author":"Zamora","year":"2004","journal-title":"Am J Transplant"},{"key":"10.1016\/j.trre.2016.04.001_bb0480","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1111\/j.1600-6143.2009.02574.x","article-title":"A multicenter study of valganciclovir prophylaxis up to day 120 in CMV-seropositive lung transplant recipients","volume":"9","author":"Monforte","year":"2009","journal-title":"Am J Transplant"},{"key":"10.1016\/j.trre.2016.04.001_bb0485","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1016\/j.healun.2008.05.009","article-title":"Ganciclovir for cytomegalovirus: a call for indefinite prophylaxis in lung transplantation","volume":"27","author":"Valentine","year":"2008","journal-title":"J Heart Lung Transplant"},{"key":"10.1016\/j.trre.2016.04.001_bb0490","doi-asserted-by":"crossref","first-page":"S163","DOI":"10.1053\/j.gastro.2005.11.050","article-title":"Optimal management of the post-intestinal transplant patient","volume":"130","author":"Horslen","year":"2006","journal-title":"Gastroenterology"},{"key":"10.1016\/j.trre.2016.04.001_bb0495","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1111\/j.1432-2277.2008.00637.x","article-title":"Present status and future perspectives of intestinal transplantation","volume":"21","author":"Pascher","year":"2008","journal-title":"Transpl Int"},{"key":"10.1016\/j.trre.2016.04.001_bb0500","doi-asserted-by":"crossref","first-page":"2782","DOI":"10.1128\/AAC.48.7.2782-2783.2004","article-title":"Pharmacokinetics of oral valganciclovir and intravenous ganciclovir administered to prevent cytomegalovirus disease in an adult patient receiving small-intestine transplantation","volume":"48","author":"Fortun Abete","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.trre.2016.04.001_bb0505","doi-asserted-by":"crossref","first-page":"ii25","DOI":"10.1093\/ndt\/gfh1079","article-title":"Cytomegalovirus: occurrence, severity, and effect on graft survival in simultaneous pancreas-kidney transplantation","volume":"20","author":"Ricart","year":"2005","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.trre.2016.04.001_bb0510","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1053\/ajkd.2002.32793","article-title":"Reassessing the impact of cytomegalovirus infection in kidney and kidney-pancreas transplantation","volume":"39","author":"Becker","year":"2002","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.trre.2016.04.001_bb0515","doi-asserted-by":"crossref","first-page":"2449","DOI":"10.1681\/ASN.2008111166","article-title":"Six-month prophylaxis is cost effective in transplant patients at high risk for cytomegalovirus infection","volume":"20","author":"Luan","year":"2009","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.trre.2016.04.001_bb0520","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1111\/ctr.12138","article-title":"Cytomegalovirus infection post-pancreas-kidney transplantation \u2014 results of antiviral prophylaxis in high-risk patients","volume":"27","author":"Fallatah","year":"2013","journal-title":"Clin Transpl"},{"key":"10.1016\/j.trre.2016.04.001_bb0525","doi-asserted-by":"crossref","first-page":"1936","DOI":"10.1111\/j.1600-6143.2011.03611.x","article-title":"Impact of cytomegalovirus disease in D+\/R\u2212 kidney transplant patients receiving 6months low-dose valganciclovir prophylaxis","volume":"11","author":"Luan","year":"2011","journal-title":"Am J Transplant"},{"key":"10.1016\/j.trre.2016.04.001_bb0530","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.transproceed.2012.04.036","article-title":"Six-month low-dose valganciclovir prophylaxis in cytomegalovirus D+\/R\u2212 kidney transplant patients receiving thymoglobulin induction","volume":"45","author":"Luan","year":"2013","journal-title":"Transplant Proc"},{"key":"10.1016\/j.trre.2016.04.001_bb0535","doi-asserted-by":"crossref","DOI":"10.1097\/TP.0000000000000570","article-title":"Evaluation of low- versus high-dose Valganciclovir for prevention of cytomegalovirus disease in high-risk renal transplant recipients","author":"Gabardi","year":"2015","journal-title":"Transplantation"},{"key":"10.1016\/j.trre.2016.04.001_bb0540","doi-asserted-by":"crossref","DOI":"10.1111\/tid.12349","article-title":"Increased risk of breakthrough infection among cytomegalovirus donor-positive\/recipient-negative kidney transplant recipients receiving lower-dose valganciclovir prophylaxis","author":"Stevens","year":"2015","journal-title":"Transpl Infect Dis"},{"key":"10.1016\/j.trre.2016.04.001_bb0545","doi-asserted-by":"crossref","first-page":"3414","DOI":"10.1016\/j.transproceed.2013.08.023","article-title":"Low-dose valganciclovir for cytomegalovirus prophylaxis in heart transplant recipients","volume":"45","author":"Julian","year":"2013","journal-title":"Transplant Proc"},{"key":"10.1016\/j.trre.2016.04.001_bb0550","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1097\/01.tp.0000251371.34968.ca","article-title":"Oral ganciclovir versus low-dose valganciclovir for prevention of cytomegalovirus disease in recipients of kidney and pancreas transplants","volume":"83","author":"Weng","year":"2007","journal-title":"Transplantation"},{"key":"10.1016\/j.trre.2016.04.001_bb0555","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1093\/ndt\/gfs531","article-title":"Clinical outcome with low-dose valacyclovir in high-risk renal transplant recipients: a 10-year experience","volume":"28","author":"Sund","year":"2013","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.trre.2016.04.001_bb0560","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1097\/TP.0b013e3181ff1493","article-title":"Extended valganciclovir prophylaxis in D+\/R\u2212 kidney transplant recipients is associated with long-term reduction in cytomegalovirus disease: two-year results of the IMPACT study","volume":"90","author":"Humar","year":"2010","journal-title":"Transplantation"},{"key":"10.1016\/j.trre.2016.04.001_bb0565","doi-asserted-by":"crossref","first-page":"2190","DOI":"10.1111\/j.1600-6143.2011.03663.x","article-title":"Cytomegalovirus replication within the lung allograft is associated with bronchiolitis obliterans syndrome","volume":"11","author":"Paraskeva","year":"2011","journal-title":"Am J Transplant"},{"key":"10.1016\/j.trre.2016.04.001_bb0570","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1111\/j.1600-6143.2012.04339.x","article-title":"Late-onset cytomegalovirus (CMV) in lung transplant recipients: can CMV serostatus guide the duration of prophylaxis?","volume":"13","author":"Schoeppler","year":"2013","journal-title":"Am J Transplant"},{"key":"10.1016\/j.trre.2016.04.001_bb0575","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1097\/SLA.0b013e3181b67725","article-title":"Five hundred intestinal and multivisceral transplantations at a single center: major advances with new challenges","volume":"250","author":"Abu-Elmagd","year":"2009","journal-title":"Ann Surg"},{"key":"10.1016\/j.trre.2016.04.001_bb0580","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1086\/516113","article-title":"Cytomegalovirus infection after intestinal transplantation in children","volume":"25","author":"Bueno","year":"1997","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.trre.2016.04.001_bb0585","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.gtc.2007.01.001","article-title":"Intestinal transplantation: current status","volume":"36","author":"Fryer","year":"2007","journal-title":"Gastroenterol Clin North Am"},{"key":"10.1016\/j.trre.2016.04.001_bb0590","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1007\/s11894-009-0035-1","article-title":"Current perspectives on pediatric intestinal transplantation","volume":"11","author":"Mazariegos","year":"2009","journal-title":"Curr Gastroenterol Rep"},{"key":"10.1016\/j.trre.2016.04.001_bb0595","series-title":"50th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)","article-title":"Infection is the leading cause of death following small-bowel transplantation","author":"San Juan","year":"2010"},{"key":"10.1016\/j.trre.2016.04.001_bb0600","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1097\/TP.0b013e3181cee42f","article-title":"International consensus guidelines on the management of cytomegalovirus in solid organ transplantation","volume":"89","author":"Kotton","year":"2010","journal-title":"Transplantation"},{"key":"10.1016\/j.trre.2016.04.001_bb0605","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.1111\/j.1600-6143.2007.01910.x","article-title":"Oral valganciclovir is noninferior to intravenous ganciclovir for the treatment of cytomegalovirus disease in solid organ transplant recipients","volume":"7","author":"Asberg","year":"2007","journal-title":"Am J Transplant"},{"key":"10.1016\/j.trre.2016.04.001_bb0610","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1002\/lt.21362","article-title":"Valganciclovir as preemptive therapy for cytomegalovirus in cytomegalovirus-seronegative liver transplant recipients of cytomegalovirus-seropositive donor allografts","volume":"14","author":"Singh","year":"2008","journal-title":"Liver Transpl"},{"key":"10.1016\/j.trre.2016.04.001_bb0615","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1111\/j.1600-6143.2011.03766.x","article-title":"High incidence of anticytomegalovirus drug resistance among D+R\u2212 kidney transplant recipients receiving preemptive therapy","volume":"12","author":"Couzi","year":"2012","journal-title":"Am J Transplant"},{"key":"10.1016\/j.trre.2016.04.001_bb0620","doi-asserted-by":"crossref","first-page":"3766","DOI":"10.1016\/j.transproceed.2005.10.075","article-title":"Efficacy and safety of valgancyclovir as preemptive therapy for the prevention of cytomegalovirus disease in solid organ transplant recipients","volume":"37","author":"Diaz-Pedroche","year":"2005","journal-title":"Transplant Proc"},{"key":"10.1016\/j.trre.2016.04.001_bb0625","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1111\/j.1600-6143.2009.02617.x","article-title":"Long-term outcomes of CMV disease treatment with valganciclovir versus IV ganciclovir in solid organ transplant recipients","volume":"9","author":"Asberg","year":"2009","journal-title":"Am J Transplant"},{"key":"10.1016\/j.trre.2016.04.001_bb0630","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1086\/342601","article-title":"Cytomegalovirus (CMV) virus load kinetics to predict recurrent disease in solid-organ transplant patients with CMV disease","volume":"186","author":"Humar","year":"2002","journal-title":"J Infect Dis"},{"key":"10.1016\/j.trre.2016.04.001_bb0635","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1111\/j.1600-6143.2010.03114.x","article-title":"Effects of the intensity of immunosuppressive therapy on outcome of treatment for CMV disease in organ transplant recipients","volume":"10","author":"Asberg","year":"2010","journal-title":"Am J Transplant"},{"key":"10.1016\/j.trre.2016.04.001_bb0640","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1111\/j.1600-6143.2009.02861.x","article-title":"Clinical predictors of relapse after treatment of primary gastrointestinal cytomegalovirus disease in solid organ transplant recipients","volume":"10","author":"Eid","year":"2010","journal-title":"Am J Transplant"},{"key":"10.1016\/j.trre.2016.04.001_bb0645","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1086\/315242","article-title":"Cytomegalovirus (CMV) DNA load predicts relapsing CMV infection after solid organ transplantation","volume":"181","author":"Sia","year":"2000","journal-title":"J Infect Dis"},{"key":"10.1016\/j.trre.2016.04.001_bb0650","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1097\/TP.0b013e318238dab3","article-title":"Valganciclovir prophylaxis versus preemptive therapy in cytomegalovirus-positive renal allograft recipients: 1-year results of a randomized clinical trial","volume":"93","author":"Witzke","year":"2012","journal-title":"Transplantation"},{"key":"10.1016\/j.trre.2016.04.001_bb0655","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1111\/tri.12378","article-title":"D. Spanish network for research in infectious, viral load, CMV-specific T-cell immune response and cytomegalovirus disease in solid organ transplant recipients at higher risk for cytomegalovirus infection during preemptive therapy","volume":"27","author":"Martin-Gandul","year":"2014","journal-title":"Transpl Int"},{"key":"10.1016\/j.trre.2016.04.001_bb0660","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1111\/ajt.12049","article-title":"Pretransplant interferon-gamma secretion by CMV-specific CD8+ T cells informs the risk of CMV replication after transplantation","volume":"13","author":"Cantisan","year":"2013","journal-title":"Am J Transplant"},{"key":"10.1016\/j.trre.2016.04.001_bb0665","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1093\/cid\/cis993","article-title":"Assessment of cytomegalovirus-specific cell-mediated immunity for the prediction of cytomegalovirus disease in high-risk solid-organ transplant recipients: a multicenter cohort study","volume":"56","author":"Manuel","year":"2013","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.trre.2016.04.001_bb0670","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1097\/TP.0b013e318200b9f0","article-title":"Impact of a preemptive strategy after 3months of valganciclovir cytomegalovirus prophylaxis in kidney transplant recipients","volume":"91","author":"Boillat Blanco","year":"2011","journal-title":"Transplantation"},{"key":"10.1016\/j.trre.2016.04.001_bb0675","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1097\/TP.0b013e31822fa4b7","article-title":"Clinical utility of molecular surveillance for cytomegalovirus after antiviral prophylaxis in high-risk solid organ transplant recipients","volume":"92","author":"Lisboa","year":"2011","journal-title":"Transplantation"},{"key":"10.1016\/j.trre.2016.04.001_bb0680","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1086\/591532","article-title":"Impact of current transplantation management on the development of cytomegalovirus disease after renal transplantation","volume":"47","author":"San Juan","year":"2008","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.trre.2016.04.001_bb0685","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1097\/00007890-199201000-00013","article-title":"Symptomatic cytomegalovirus disease in the cytomegalovirus antibody seropositive renal transplant recipient treated with OKT3","volume":"53","author":"Hibberd","year":"1992","journal-title":"Transplantation"},{"key":"10.1016\/j.trre.2016.04.001_bb0690","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1097\/00007890-200010270-00007","article-title":"A prospective study of the natural course of cytomegalovirus infection and disease in renal allograft recipients","volume":"70","author":"Sagedal","year":"2000","journal-title":"Transplantation"},{"key":"10.1016\/j.trre.2016.04.001_bb0695","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1007\/s10875-012-9670-7","article-title":"Simultaneous monitoring of cytomegalovirus-specific antibody and T-cell levels in seropositive heart transplant recipients","volume":"32","author":"Carbone","year":"2012","journal-title":"J Clin Immunol"},{"key":"10.1016\/j.trre.2016.04.001_bb0700","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.intimp.2004.09.006","article-title":"Hypogammaglobulinemia after heart transplantation: use of intravenous immunoglobulin replacement therapy in relapsing CMV disease","volume":"5","author":"Sarmiento","year":"2005","journal-title":"Int Immunopharmacol"},{"key":"10.1016\/j.trre.2016.04.001_bb0705","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/j.intimp.2008.09.013","article-title":"Immune monitoring of anti cytomegalovirus antibodies and risk of cytomegalovirus disease in heart transplantation","volume":"9","author":"Sarmiento","year":"2009","journal-title":"Int Immunopharmacol"},{"key":"10.1016\/j.trre.2016.04.001_bb0710","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1111\/tri.12131","article-title":"Alterations of naive and memory B-cell subsets are associated with risk of rejection and infection in heart recipients","volume":"26","author":"Lanio","year":"2013","journal-title":"Transpl Int"},{"key":"10.1016\/j.trre.2016.04.001_bb0715","series-title":"ISHLT 35th Annual Meeting and Scientific Sessions, Nice, France","article-title":"Hypogammaglobulinemia can be immunomodulated as a risk factor of infection in heart recipients by preventive use of intravenous immunoglobulin: results of a clinical trial","author":"Sarmiento","year":"2015"},{"key":"10.1016\/j.trre.2016.04.001_bb0720","first-page":"33","article-title":"Effect of CMV-immunoglobulins (cytotect biotest) prophylaxis on CMV pneumonia after lung transplantation","volume":"34","author":"Solidoro","year":"2011","journal-title":"New Microbiol"},{"key":"10.1016\/j.trre.2016.04.001_bb0725","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1128\/CMR.00034-08","article-title":"Immunobiology of human cytomegalovirus: from bench to bedside","volume":"22","author":"Crough","year":"2009","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.trre.2016.04.001_bb0730","doi-asserted-by":"crossref","first-page":"1678","DOI":"10.1093\/cid\/cis818","article-title":"State-of-the-art monitoring of cytomegalovirus-specific cell-mediated immunity after organ transplant: a primer for the clinician","volume":"55","author":"Egli","year":"2012","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.trre.2016.04.001_bb0735","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0106044","article-title":"Human cytomegalovirus (HCMV)-specific CD4+ and CD8+ T cells are both required for prevention of HCMV disease in seropositive solid-organ transplant recipients","volume":"9","author":"Gabanti","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.trre.2016.04.001_bb0740","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1086\/644509","article-title":"Common features of gammadelta T cells and CD8(+) alphabeta T cells responding to human cytomegalovirus infection in kidney transplant recipients","volume":"200","author":"Couzi","year":"2009","journal-title":"J Infect Dis"},{"key":"10.1016\/j.trre.2016.04.001_bb0745","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0043937","article-title":"An analysis of regulatory T-cell and Th-17 cell dynamics during cytomegalovirus replication in solid organ transplant recipients","volume":"7","author":"Egli","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.trre.2016.04.001_bb0750","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.trim.2014.08.002","article-title":"Expression of killer cell immunoglobulin-like receptors (KIRs) by natural killer cells during acute CMV infection after kidney transplantation","volume":"31","author":"de Rham","year":"2014","journal-title":"Transpl Immunol"},{"key":"10.1016\/j.trre.2016.04.001_bb0755","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1111\/ajt.12532","article-title":"KIR and HLA interactions are associated with control of primary CMV infection in solid organ transplant recipients","volume":"14","author":"van Duin","year":"2014","journal-title":"Am J Transplant"},{"key":"10.1016\/j.trre.2016.04.001_bb0760","doi-asserted-by":"crossref","first-page":"3796","DOI":"10.1016\/j.vaccine.2014.05.004","article-title":"Human cytomegalovirus gH\/gL\/UL128\/UL130\/UL131A complex elicits potently neutralizing antibodies in mice","volume":"32","author":"Wen","year":"2014","journal-title":"Vaccine"},{"key":"10.1016\/j.trre.2016.04.001_bb0765","doi-asserted-by":"crossref","first-page":"2822","DOI":"10.1099\/vir.0.000203","article-title":"Role of cytomegalovirus (CMV)-specific polyfunctional CD8+ T-cells and antibodies neutralizing virus epithelial infection in the control of CMV infection in an allogeneic stem-cell transplantation setting","volume":"96","author":"Gimenez","year":"2015","journal-title":"J Gen Virol"},{"key":"10.1016\/j.trre.2016.04.001_bb0770","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1097\/00007890-200105150-00018","article-title":"Levels of virus-specific CD4 T cells correlate with cytomegalovirus control and predict virus-induced disease after renal transplantation","volume":"71","author":"Sester","year":"2001","journal-title":"Transplantation"},{"key":"10.1016\/j.trre.2016.04.001_bb0775","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1111\/j.1600-6143.2005.00871.x","article-title":"Differences in CMV-specific T-cell levels and long-term susceptibility to CMV infection after kidney, heart and lung transplantation","volume":"5","author":"Sester","year":"2005","journal-title":"Am J Transplant"},{"key":"10.1016\/j.trre.2016.04.001_bb0780","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1111\/j.1600-6143.2003.00647.x","article-title":"Cellular immune responses to cytomegalovirus in renal transplant recipients","volume":"5","author":"Radha","year":"2005","journal-title":"Am J Transplant"},{"key":"10.1016\/j.trre.2016.04.001_bb0785","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1084\/jem.20042384","article-title":"Protection from cytomegalovirus after transplantation is correlated with immediate early 1-specific CD8 T cells","volume":"201","author":"Bunde","year":"2005","journal-title":"J Exp Med"},{"key":"10.1016\/j.trre.2016.04.001_bb0790","doi-asserted-by":"crossref","first-page":"2356","DOI":"10.1111\/j.1600-6143.2006.01488.x","article-title":"Monitoring of human cytomegalovirus-specific CD4 and CD8 T-cell immunity in patients receiving solid organ transplantation","volume":"6","author":"Gerna","year":"2006","journal-title":"Am J Transplant"},{"key":"10.1016\/j.trre.2016.04.001_bb0795","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1111\/j.1432-2277.2009.01017.x","article-title":"A prospective longitudinal analysis of cytomegalovirus (CMV)-specific CD4+ and CD8+ T cells in kidney allograft recipients at risk of CMV infection","volume":"23","author":"Eid","year":"2010","journal-title":"Transpl Int"},{"key":"10.1016\/j.trre.2016.04.001_bb0800","doi-asserted-by":"crossref","first-page":"2463","DOI":"10.1111\/j.1600-6143.2011.03636.x","article-title":"Virologic and immunologic monitoring of cytomegalovirus to guide preemptive therapy in solid-organ transplantation","volume":"11","author":"Gerna","year":"2011","journal-title":"Am J Transplant"},{"key":"10.1016\/j.trre.2016.04.001_bb0805","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1093\/infdis\/jir624","article-title":"Primary cytomegalovirus phosphoprotein 65-specific CD8+ T-cell responses and T-bet levels predict immune control during early chronic infection in lung transplant recipients","volume":"204","author":"Pipeling","year":"2011","journal-title":"J Infect Dis"},{"key":"10.1016\/j.trre.2016.04.001_bb0810","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1097\/TP.0b013e3182115ba2","article-title":"Therapeutic effect of the acquisition of CMV-specific immune response during pre-emptive treatment","volume":"91","author":"BenMarzouk-Hidalgo","year":"2011","journal-title":"Transplantation"},{"key":"10.1016\/j.trre.2016.04.001_bb0815","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1097\/01.TP.0000438025.96334.eb","article-title":"Pretransplant CD8 T-cell response to IE-1 discriminates seropositive kidney recipients at risk of developing CMV infection posttransplant","volume":"97","author":"Lopez-Oliva","year":"2014","journal-title":"Transplantation"},{"key":"10.1016\/j.trre.2016.04.001_bb0820","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1111\/j.1399-3062.2006.00199.x","article-title":"Ex vivo monitoring of human cytomegalovirus-specific CD8+ T-cell responses using QuantiFERON-CMV","volume":"9","author":"Walker","year":"2007","journal-title":"Transpl Infect Dis"},{"key":"10.1016\/j.trre.2016.04.001_bb0825","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1111\/j.1600-6143.2009.02618.x","article-title":"Cell-mediated immunity to predict cytomegalovirus disease in high-risk solid organ transplant recipients","volume":"9","author":"Kumar","year":"2009","journal-title":"Am J Transplant"},{"key":"10.1016\/j.trre.2016.04.001_bb0830","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1097\/TP.0b013e31823c1cd4","article-title":"Clinical utility of cytomegalovirus cell-mediated immunity in transplant recipients with cytomegalovirus viremia","volume":"93","author":"Lisboa","year":"2012","journal-title":"Transplantation"},{"key":"10.1016\/j.trre.2016.04.001_bb0835","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1086\/654931","volume":"202","author":"Abate","year":"2010","journal-title":"J Infect Dis"},{"key":"10.1016\/j.trre.2016.04.001_bb0840","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1016\/j.transproceed.2011.03.024","article-title":"Evaluation and significance of cytomegalovirus-specific cellular immune response in lung transplant recipients","volume":"43","author":"Costa","year":"2011","journal-title":"Transplant Proc"},{"key":"10.1016\/j.trre.2016.04.001_bb0845","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/1479-5876-6-29","article-title":"Cytomegalovirus-specific T-cell responses and viral replication in kidney transplant recipients","volume":"6","author":"Egli","year":"2008","journal-title":"J Transl Med"},{"key":"10.1016\/j.trre.2016.04.001_bb0850","doi-asserted-by":"crossref","first-page":"2501","DOI":"10.1128\/JCM.00563-13","article-title":"Comparison of cytomegalovirus (CMV) enzyme-linked immunosorbent spot and CMV quantiferon gamma interferon-releasing assays in assessing risk of CMV infection in kidney transplant recipients","volume":"51","author":"Abate","year":"2013","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.trre.2016.04.001_bb0855","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1111\/j.1399-3046.2011.01531.x","article-title":"Dynamics of cell-mediated immune responses to cytomegalovirus in pediatric transplantation recipients","volume":"16","author":"Patel","year":"2012","journal-title":"Pediatr Transplant"},{"key":"10.1016\/j.trre.2016.04.001_bb0860","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1111\/ajt.12256","article-title":"Pretransplant immediately early-1-specific T cell responses provide protection for CMV infection after kidney transplantation","volume":"13","author":"Bestard","year":"2013","journal-title":"Am J Transplant"},{"key":"10.1016\/j.trre.2016.04.001_bb0865","doi-asserted-by":"crossref","first-page":"2243","DOI":"10.1097\/00007890-200006150-00005","article-title":"Characterization of CMVpp65-specific CD8+ T lymphocytes using MHC tetramers in kidney transplant patients and healthy participants","volume":"69","author":"Engstrand","year":"2000","journal-title":"Transplantation"},{"key":"10.1016\/j.trre.2016.04.001_bb0870","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1111\/j.1399-0012.2009.00976.x","article-title":"CMV-specific T-cell immunity, viral load, and clinical outcome in seropositive renal transplant recipients: a pilot study","volume":"24","author":"Sund","year":"2010","journal-title":"Clin Transpl"},{"key":"10.1016\/j.trre.2016.04.001_bb0875","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1086\/523652","article-title":"Programmed death-1 expression in liver transplant recipients as a prognostic indicator of cytomegalovirus disease","volume":"197","author":"La Rosa","year":"2008","journal-title":"J Infect Dis"},{"key":"10.1016\/j.trre.2016.04.001_bb0880","doi-asserted-by":"crossref","first-page":"3132","DOI":"10.1111\/ajt.12480","article-title":"PD-1 analysis on CD28(\u2212) CD27(\u2212) CD4 T cells allows stimulation-independent assessment of CMV viremic episodes in transplant recipients","volume":"13","author":"Dirks","year":"2013","journal-title":"Am J Transplant"},{"key":"10.1016\/j.trre.2016.04.001_bb0885","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1002\/cyto.b.20186","article-title":"Measurement of antigen specific immune responses: 2006 update","volume":"72","author":"Li Pira","year":"2007","journal-title":"Cytometry B Clin Cytom"},{"key":"10.1016\/j.trre.2016.04.001_bb0890","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1038\/nri777","article-title":"Tracking T cells with tetramers: new tales from new tools","volume":"2","author":"Klenerman","year":"2002","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.trre.2016.04.001_bb0895","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1097\/01.tp.0000234837.02126.70","article-title":"Assessing relative risks of infection and rejection: a meta-analysis using an immune function assay","volume":"82","author":"Kowalski","year":"2006","journal-title":"Transplantation"},{"key":"10.1016\/j.trre.2016.04.001_bb0900","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1097\/TP.0b013e3182466248","article-title":"Can immune cell function assay identify patients at risk of infection or rejection? A meta-analysis","volume":"93","author":"Ling","year":"2012","journal-title":"Transplantation"},{"key":"10.1016\/j.trre.2016.04.001_bb0905","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1111\/j.1600-6143.2006.01641.x","article-title":"Recovery of functional memory T cells in lung transplant recipients following induction therapy with alemtuzumab","volume":"7","author":"Zeevi","year":"2007","journal-title":"Am J Transplant"},{"key":"10.1016\/j.trre.2016.04.001_bb0910","doi-asserted-by":"crossref","first-page":"1852","DOI":"10.1097\/TP.0b013e3181a75ad2","article-title":"Experience with immune monitoring in lung transplant recipients: correlation of low immune function with infection","volume":"87","author":"Husain","year":"2009","journal-title":"Transplantation"},{"key":"10.1016\/j.trre.2016.04.001_bb0915","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.trim.2010.11.006","article-title":"Immunologic parameters and viral infections in patients desensitized with intravenous immunoglobulin and rituximab","volume":"24","author":"Ge","year":"2011","journal-title":"Transpl Immunol"},{"key":"10.1016\/j.trre.2016.04.001_bb0920","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1016\/j.transproceed.2011.02.043","article-title":"\u201cImmuknow\u201d to measurement of cell-mediated immunity in renal transplant recipients undergoing short-term evaluation","volume":"43","author":"De Paolis","year":"2011","journal-title":"Transplant Proc"},{"key":"10.1016\/j.trre.2016.04.001_bb0925","series-title":"54th Annual Interscience Congress on Antimicrobial Agents and Chemotherapy (ICAAC), September 6\u20139","article-title":"Functional monitoring of cell-mediated immune response predicts the ocurrence of cytomegalovirus (CMV) disease in kidney transplant (KT) recipients","author":"L.-M.F.","year":"2014"},{"key":"10.1016\/j.trre.2016.04.001_bb0930","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1093\/cid\/ciu589","article-title":"Preformed frequencies of cytomegalovirus (CMV)-specific memory T and B cells identify protected CMV-sensitized individuals among seronegative kidney transplant recipients","volume":"59","author":"Lucia","year":"2014","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.trre.2016.04.001_bb0935","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/S0140-6736(88)90685-X","article-title":"Symptomatic cytomegalovirus infection in seropositive kidney recipients: reinfection with donor virus rather than reactivation of recipient virus","volume":"2","author":"Grundy","year":"1988","journal-title":"Lancet"},{"key":"10.1016\/j.trre.2016.04.001_bb0940","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.jcv.2007.10.006","article-title":"Donor and recipient CMV serostatus and antigenemia after renal transplantation: an analysis of 486 patients","volume":"41","author":"Hughes","year":"2008","journal-title":"J Clin Virol"},{"key":"10.1016\/j.trre.2016.04.001_bb0945","doi-asserted-by":"crossref","first-page":"2457","DOI":"10.1111\/j.1600-6143.2012.04087.x","article-title":"Cytomegalovirus replication kinetics in solid organ transplant recipients managed by preemptive therapy","volume":"12","author":"Atabani","year":"2012","journal-title":"Am J Transplant"},{"key":"10.1016\/j.trre.2016.04.001_bb0950","doi-asserted-by":"crossref","first-page":"1698","DOI":"10.1681\/ASN.2013040340","article-title":"Impaired direct priming of CD8 T cells by donor-derived cytomegalovirus following kidney transplantation","volume":"24","author":"Shabir","year":"2013","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.trre.2016.04.001_bb0955","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1002\/lt.24078","article-title":"Risk factors for cytomegalovirus reactivation after liver transplantation: can pre-transplant cytomegalovirus antibody titers predict outcome?","volume":"21","author":"Bruminhent","year":"2015","journal-title":"Liver Transpl"},{"key":"10.1016\/j.trre.2016.04.001_bb0960","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1007\/s11908-013-0369-6","article-title":"Clinical experience with immune monitoring for cytomegalovirus in solid-organ transplant recipients","volume":"15","author":"Manuel","year":"2013","journal-title":"Curr Infect Dis Rep"},{"key":"10.1016\/j.trre.2016.04.001_bb0965","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1056\/NEJMoa0804749","article-title":"Vaccine prevention of maternal cytomegalovirus infection","volume":"360","author":"Pass","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.trre.2016.04.001_bb0970","doi-asserted-by":"crossref","first-page":"525","DOI":"10.7326\/0003-4819-114-7-525","article-title":"Effect of Towne live virus vaccine on cytomegalovirus disease after renal transplant. A controlled trial","volume":"114","author":"Plotkin","year":"1991","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.trre.2016.04.001_bb0975","first-page":"1176","article-title":"Multicenter trial of Towne strain attenuated virus vaccine in seronegative renal transplant recipients","volume":"58","author":"Plotkin","year":"1994","journal-title":"Transplantation"},{"key":"10.1016\/j.trre.2016.04.001_bb0980","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1016\/S0140-6736(11)60136-0","article-title":"Cytomegalovirus glycoprotein-B vaccine with MF59 adjuvant in transplant recipients: a phase 2 randomised placebo-controlled trial","volume":"377","author":"Griffiths","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.trre.2016.04.001_bb0985","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/S1473-3099(11)70344-9","article-title":"A novel therapeutic cytomegalovirus DNA vaccine in allogeneic haemopoietic stem-cell transplantation: a randomised, double-blind, placebo-controlled, phase 2 trial","volume":"12","author":"Kharfan-Dabaja","year":"2012","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.trre.2016.04.001_bb0990","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1034\/j.1600-6143.2002.20907.x","article-title":"The impact of cytomegalovirus infection and disease on rejection episodes in renal allograft recipients","volume":"2","author":"Sagedal","year":"2002","journal-title":"Am J Transplant"},{"key":"10.1016\/j.trre.2016.04.001_bb0995","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1097\/00007890-200103270-00013","article-title":"Cytomegalovirus infection and graft rejection in renal transplantation","volume":"71","author":"Dickenmann","year":"2001","journal-title":"Transplantation"},{"key":"10.1016\/j.trre.2016.04.001_bb1000","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1016\/S0041-1345(03)00715-2","article-title":"Significance of cytomegalovirus infection in renal transplantation","volume":"35","author":"Sola","year":"2003","journal-title":"Transplant Proc"},{"key":"10.1016\/j.trre.2016.04.001_bb1005","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1097\/TP.0b013e318192ded5","article-title":"Effect of cytomegalovirus viremia on subclinical rejection or interstitial fibrosis and tubular atrophy in protocol biopsy at 3months in renal allograft recipients managed by preemptive therapy or antiviral prophylaxis","volume":"87","author":"Reischig","year":"2009","journal-title":"Transplantation"},{"key":"10.1016\/j.trre.2016.04.001_bb1010","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1093\/cid\/cir619","article-title":"Intragraft cytomegalovirus protein expression is associated with reduced renal allograft survival","volume":"53","author":"Dzabic","year":"2011","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.trre.2016.04.001_bb1015","doi-asserted-by":"crossref","first-page":"3760","DOI":"10.1016\/j.transproceed.2005.08.058","article-title":"Cytomegalovirus replication and \u201cherpesvirus burden\u201d as risk factor of cardiovascular events in the first year after renal transplantation","volume":"37","author":"Gomez","year":"2005","journal-title":"Transplant Proc"},{"key":"10.1016\/j.trre.2016.04.001_bb1020","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1016\/j.transproceed.2007.02.026","article-title":"The association between cytomegalovirus infection and atherosclerotic events in renal transplant recipients","volume":"39","author":"Ozdemir","year":"2007","journal-title":"Transplant Proc"},{"key":"10.1016\/j.trre.2016.04.001_bb1025","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1097\/00007890-200110270-00011","article-title":"Cytomegalovirus disease is not a major risk factor for ischemic heart disease after renal transplantation","volume":"72","author":"Hernandez","year":"2001","journal-title":"Transplantation"},{"key":"10.1016\/j.trre.2016.04.001_bb1030","doi-asserted-by":"crossref","DOI":"10.1097\/TP.0000000000000522","article-title":"Reduced rate of cardiovascular death after cytomegalovirus prophylaxis in renal transplant recipients","author":"Opelz","year":"2015","journal-title":"Transplantation"},{"key":"10.1016\/j.trre.2016.04.001_bb1035","first-page":"139","article-title":"The impact of cytomegalovirus infection on new-onset diabetes mellitus after kidney transplantation: a review on current findings","volume":"3","author":"Einollahi","year":"2014","journal-title":"J Nephropathol"},{"key":"10.1016\/j.trre.2016.04.001_bb1040","doi-asserted-by":"crossref","first-page":"2064","DOI":"10.1097\/01.TP.0000069234.04901.A3","article-title":"Bronchiolitis obliterans syndrome and early human cytomegalovirus DNAaemia dynamics after lung transplantation","volume":"75","author":"Westall","year":"2003","journal-title":"Transplantation"},{"key":"10.1016\/j.trre.2016.04.001_bb1045","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1164\/rccm.200911-1786OC","article-title":"Cytomegalovirus pneumonitis is a risk for bronchiolitis obliterans syndrome in lung transplantation","volume":"181","author":"Snyder","year":"2010","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.trre.2016.04.001_bb1050","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1086\/528689","article-title":"Ganciclovir\/valganciclovir prophylaxis decreases cytomegalovirus-related events and bronchiolitis obliterans syndrome after lung transplantation","volume":"46","author":"Chmiel","year":"2008","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.trre.2016.04.001_bb1055","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1186\/1471-2334-13-582","article-title":"Lower incidence of CMV infection and acute rejections with valganciclovir prophylaxis in lung transplant recipients","volume":"13","author":"Johansson","year":"2013","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.trre.2016.04.001_bb1060","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1097\/TP.0b013e3181963262","article-title":"Lack of association between beta-herpesvirus infection and bronchiolitis obliterans syndrome in lung transplant recipients in the era of antiviral prophylaxis","volume":"87","author":"Manuel","year":"2009","journal-title":"Transplantation"},{"key":"10.1016\/j.trre.2016.04.001_bb1065","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1164\/rccm.200310-1405OC","article-title":"Treated cytomegalovirus pneumonia is not associated with bronchiolitis obliterans syndrome","volume":"170","author":"Tamm","year":"2004","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.trre.2016.04.001_bb1070","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1097\/00007890-200001150-00007","article-title":"An association between cytomegalovirus infection and chronic rejection after liver transplantation","volume":"69","author":"Evans","year":"2000","journal-title":"Transplantation"},{"key":"10.1016\/j.trre.2016.04.001_bb1075","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1053\/jlts.2002.32282","article-title":"Impact of cytomegalovirus infection, year of transplantation, and donor age on outcomes after liver transplantation for hepatitis C","volume":"8","author":"Burak","year":"2002","journal-title":"Liver Transpl"},{"key":"10.1016\/j.trre.2016.04.001_bb1080","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1002\/hep.1840160113","article-title":"Lack of association between cytomegalovirus infection, HLA matching and the vanishing bile duct syndrome after liver transplantation","volume":"16","author":"Paya","year":"1992","journal-title":"Hepatology"},{"key":"10.1016\/j.trre.2016.04.001_bb1085","doi-asserted-by":"crossref","first-page":"S171","DOI":"10.1111\/j.1432-2277.1996.tb01599.x","article-title":"Cytomegalovirus infection does not increase the risk of vanishing bile duct syndrome after liver transplantation","volume":"9","author":"van den Berg","year":"1996","journal-title":"Transpl Int"},{"key":"10.1016\/j.trre.2016.04.001_bb1090","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1097\/TP.0000000000000160","article-title":"Cytomegalovirus serology and replication remain associated with solid organ graft rejection and graft loss in the era of prophylactic treatment","volume":"98","author":"Stern","year":"2014","journal-title":"Transplantation"},{"key":"10.1016\/j.trre.2016.04.001_bb1095","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1097\/TP.0b013e3182472876","article-title":"Association of cytomegalovirus infection and disease with recurrent hepatitis C after liver transplantation","volume":"93","author":"Bosch","year":"2011","journal-title":"Transplantation"},{"key":"10.1016\/j.trre.2016.04.001_bb1100","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1097\/01.TP.0000088668.28950.7C","article-title":"Progression of liver fibrosis in patients with chronic hepatitis C after orthotopic liver transplantation","volume":"76","author":"Chopra","year":"2003","journal-title":"Transplantation"},{"key":"10.1016\/j.trre.2016.04.001_bb1105","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1097\/00007890-200011270-00010","article-title":"The influence of cytomegalovirus viraemia on the outcome of recurrent hepatitis C after liver transplantation","volume":"70","author":"Teixeira","year":"2000","journal-title":"Transplantation"},{"key":"10.1016\/j.trre.2016.04.001_bb1110","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1097\/01.TP.0000157867.98649.F5","article-title":"Indirect outcomes associated with cytomegalovirus (opportunistic infections, hepatitis C virus sequelae, and mortality) in liver-transplant recipients with the use of preemptive therapy for 13years","volume":"79","author":"Singh","year":"2005","journal-title":"Transplantation"},{"key":"10.1016\/j.trre.2016.04.001_bb1115","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1097\/00007890-199808150-00003","article-title":"Cytomegalovirus and its association with hepatic artery thrombosis after liver transplantation","volume":"66","author":"Madalosso","year":"1998","journal-title":"Transplantation"},{"key":"10.1016\/j.trre.2016.04.001_bb1120","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1053\/jlts.2001.22040","article-title":"Hepatic artery thrombosis after orthotopic liver transplantation: a review of nonsurgical causes","volume":"7","author":"Pastacaldi","year":"2001","journal-title":"Liver Transpl"},{"key":"10.1016\/j.trre.2016.04.001_bb1125","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1097\/00007890-200103270-00014","article-title":"Uni- and multi-variate analysis of risk factors for early and late hepatic artery thrombosis after liver transplantation","volume":"71","author":"Oh","year":"2001","journal-title":"Transplantation"},{"key":"10.1016\/j.trre.2016.04.001_bb1130","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1111\/j.1600-6143.2008.02541.x","article-title":"Early hepatic artery thrombosis after liver transplantation: a systematic review of the incidence, outcome and risk factors","volume":"9","author":"Bekker","year":"2009","journal-title":"Am J Transplant"},{"key":"10.1016\/j.trre.2016.04.001_bb1135","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1097\/01.TP.0000090163.48433.48","article-title":"Cytomegalovirus infection status predicts progression of heart-transplant vasculopathy","volume":"76","author":"Fateh-Moghadam","year":"2003","journal-title":"Transplantation"},{"key":"10.1016\/j.trre.2016.04.001_bb1140","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1016\/j.healun.2015.03.015","article-title":"Influence of cytomegalovirus infection in the development of cardiac allograft vasculopathy after heart transplantation","volume":"34","author":"Delgado","year":"2015","journal-title":"J Heart Lung Transplant"},{"key":"10.1016\/j.trre.2016.04.001_bb1145","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1097\/01.tp.0000229039.87735.76","article-title":"Acute rejection and cardiac allograft vascular disease is reduced by suppression of subclinical cytomegalovirus infection","volume":"82","author":"Potena","year":"2006","journal-title":"Transplantation"},{"key":"10.1016\/j.trre.2016.04.001_bb1150","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/j.healun.2009.02.009","article-title":"Prophylaxis versus preemptive anti-cytomegalovirus approach for prevention of allograft vasculopathy in heart transplant recipients","volume":"28","author":"Potena","year":"2009","journal-title":"J Heart Lung Transplant"},{"key":"10.1016\/j.trre.2016.04.001_bb1155","doi-asserted-by":"crossref","first-page":"2866","DOI":"10.1016\/j.transproceed.2007.09.013","article-title":"The influence of cytomegalovirus infection, confirmed by pp65 antigen presence, on the development of cardiac allograft vasculopathy","volume":"39","author":"Zakliczynski","year":"2007","journal-title":"Transplant Proc"},{"key":"10.1016\/j.trre.2016.04.001_bb1160","doi-asserted-by":"crossref","first-page":"3219","DOI":"10.1016\/j.transproceed.2009.07.068","article-title":"Cytomegalovirus infection does not accelerate microvasculopathy development in heart transplant recipients","volume":"41","author":"Zakliczynski","year":"2009","journal-title":"Transplant Proc"},{"key":"10.1016\/j.trre.2016.04.001_bb1165","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1111\/j.1600-6143.2009.02935.x","article-title":"Incidence of and risk factors for posttransplant diabetes mellitus after pancreas transplantation","volume":"10","author":"Neidlinger","year":"2010","journal-title":"Am J Transplant"},{"key":"10.1016\/j.trre.2016.04.001_bb1170","doi-asserted-by":"crossref","first-page":"1716","DOI":"10.1097\/00007890-199606270-00009","article-title":"Incidence and predictors of cytomegalovirus pneumonia in orthotopic liver transplant recipients. Boston Center for Liver Transplantation CMVIG study group","volume":"61","author":"Falagas","year":"1996","journal-title":"Transplantation"},{"key":"10.1016\/j.trre.2016.04.001_bb1175","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1086\/514340","article-title":"Risk factors, clinical characteristics, and outcome of Nocardia infection in organ transplant recipients: a matched case\u2013control study","volume":"44","author":"Peleg","year":"2007","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.trre.2016.04.001_bb1180","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/S0002-9343(97)80021-6","article-title":"The independent role of cytomegalovirus as a risk factor for invasive fungal disease in orthotopic liver transplant recipients. Boston Center for Liver Transplantation CMVIG-study group. Cytogam, MedImmune, Inc. Gaithersburg, Maryland","volume":"103","author":"George","year":"1997","journal-title":"Am J Med"},{"key":"10.1016\/j.trre.2016.04.001_bb1185","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1053\/jlts.2002.36239","article-title":"Risk factors for invasive aspergillosis in liver transplant recipients","volume":"8","author":"Fortun","year":"2002","journal-title":"Liver Transpl"},{"key":"10.1016\/j.trre.2016.04.001_bb1190","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1086\/430602","article-title":"Risk factors for invasive aspergillosis in solid-organ transplant recipients: a case\u2013control study","volume":"41","author":"Gavalda","year":"2005","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.trre.2016.04.001_bb1195","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1086\/514142","article-title":"Posttransplant lymphoproliferative disease in primary Epstein\u2013Barr virus infection after liver transplantation: the role of cytomegalovirus disease","volume":"176","author":"Manez","year":"1997","journal-title":"J Infect Dis"},{"key":"10.1016\/j.trre.2016.04.001_bb1200","doi-asserted-by":"crossref","first-page":"E430","DOI":"10.1111\/j.1399-0012.2011.01464.x","article-title":"Risk factors for post-transplant lymphoproliferative disease in patients with cystic fibrosis","volume":"25","author":"Saueressig","year":"2011","journal-title":"Clin Transpl"},{"key":"10.1016\/j.trre.2016.04.001_bb1205","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1128\/CVI.00214-09","article-title":"Age-dependent association between low frequency of CD27\/CD28 expression on pp65 CD8+ T cells and cytomegalovirus replication after transplantation","volume":"16","author":"Cantisan","year":"2009","journal-title":"Clin Vaccine Immunol"},{"key":"10.1016\/j.trre.2016.04.001_bb1210","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1111\/j.1523-1755.2004.00735.x","article-title":"Impact of early cytomegalovirus infection and disease on long-term recipient and kidney graft survival","volume":"66","author":"Sagedal","year":"2004","journal-title":"Kidney Int"},{"key":"10.1016\/j.trre.2016.04.001_bb1215","doi-asserted-by":"crossref","first-page":"S78","DOI":"10.1111\/j.1600-6143.2009.02897.x","article-title":"Cytomegalovirus in solid organ transplant recipients","volume":"9","author":"Humar","year":"2009","journal-title":"Am J Transplant"},{"key":"10.1016\/j.trre.2016.04.001_bb1220","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1159\/000180580","article-title":"Prediction of creatinine clearance from serum creatinine","volume":"16","author":"Cockcroft","year":"1976","journal-title":"Nephron"},{"key":"10.1016\/j.trre.2016.04.001_bb1225","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1111\/tid.12133","article-title":"Critical analysis of valganciclovir dosing and renal function on the development of cytomegalovirus infection in kidney transplantation","volume":"15","author":"Posadas Salas","year":"2013","journal-title":"Transpl Infect Dis"},{"key":"10.1016\/j.trre.2016.04.001_bb1230","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1086\/523590","article-title":"Valganciclovir as treatment for cytomegalovirus disease in solid organ transplant recipients","volume":"46","author":"Len","year":"2008","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.trre.2016.04.001_bb1235","doi-asserted-by":"crossref","first-page":"1983","DOI":"10.1517\/14656566.2010.492395","article-title":"Strategies for managing cytomegalovirus in transplant recipients","volume":"11","author":"Razonable","year":"2010","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.trre.2016.04.001_bb1240","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1007\/s11908-014-0419-8","article-title":"Emerging cytomegalovirus management strategies after solid organ transplantation: challenges and opportunities","volume":"16","author":"Beam","year":"2014","journal-title":"Curr Infect Dis Rep"},{"key":"10.1016\/j.trre.2016.04.001_bb1245","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1111\/ajt.12103","article-title":"Cytomegalovirus in solid organ transplantation","volume":"13","author":"Razonable","year":"2013","journal-title":"Am J Transplant"},{"key":"10.1016\/j.trre.2016.04.001_bb1250","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1111\/j.1399-0012.2007.00761.x","article-title":"Emergence of drug-resistant cytomegalovirus in the era of valganciclovir prophylaxis: therapeutic implications and outcomes","volume":"22","author":"Eid","year":"2008","journal-title":"Clin Transpl"},{"key":"10.1016\/j.trre.2016.04.001_bb1255","doi-asserted-by":"crossref","first-page":"2628","DOI":"10.1093\/jac\/dkq368","article-title":"Drug-resistant cytomegalovirus in transplant recipients: a French cohort study","volume":"65","author":"Hantz","year":"2010","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.trre.2016.04.001_bb1260","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1097\/TP.0b013e31821fad25","article-title":"Incidence and outcomes of ganciclovir-resistant cytomegalovirus infections in 1244 kidney transplant recipients","volume":"92","author":"Myhre","year":"2011","journal-title":"Transplantation"},{"key":"10.1016\/j.trre.2016.04.001_bb1265","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1097\/TP.0b013e31828555ac","article-title":"Use of high-dose ganciclovir for the treatment of cytomegalovirus replication in solid organ transplant patients with ganciclovir resistance-inducing mutations","volume":"95","author":"Gracia-Ahufinger","year":"2013","journal-title":"Transplantation"},{"key":"10.1016\/j.trre.2016.04.001_bb1270","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1086\/340101","article-title":"Combination antiviral therapy for ganciclovir-resistant cytomegalovirus infection in solid-organ transplant recipients","volume":"34","author":"Mylonakis","year":"2002","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.trre.2016.04.001_bb1275","doi-asserted-by":"crossref","first-page":"435","DOI":"10.2217\/17460794.3.5.435","article-title":"Maribavir: a new oral anti-cytomegalovirus drug","volume":"3","author":"Pescovitz","year":"2008","journal-title":"Futur Virol"},{"key":"10.1016\/j.trre.2016.04.001_bb1280","doi-asserted-by":"crossref","first-page":"5403","DOI":"10.1182\/blood-2007-11-121558","article-title":"Maribavir prophylaxis for prevention of cytomegalovirus infection in allogeneic stem cell transplant recipients: a multicenter, randomized, double-blind, placebo-controlled, dose-ranging study","volume":"111","author":"Winston","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.trre.2016.04.001_bb1285","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/S1473-3099(11)70024-X","article-title":"Maribavir prophylaxis for prevention of cytomegalovirus disease in recipients of allogeneic stem-cell transplants: a phase 3, double-blind, placebo-controlled, randomised trial","volume":"11","author":"Marty","year":"2011","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.trre.2016.04.001_bb1290","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1111\/j.1399-3062.2010.00550.x","article-title":"Oral maribavir for treatment of refractory or resistant cytomegalovirus infections in transplant recipients","volume":"12","author":"Avery","year":"2010","journal-title":"Transpl Infect Dis"},{"key":"10.1016\/j.trre.2016.04.001_bb1295","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1056\/NEJMoa1303688","article-title":"CMX001 to prevent cytomegalovirus disease in hematopoietic-cell transplantation","volume":"369","author":"Marty","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.trre.2016.04.001_bb1300","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1056\/NEJMoa1309533","article-title":"Letermovir for cytomegalovirus prophylaxis in hematopoietic-cell transplantation","volume":"370","author":"Chemaly","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.trre.2016.04.001_bb1305","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1111\/j.1600-6143.2011.03530.x","article-title":"First report of successful treatment of multidrug-resistant cytomegalovirus disease with the novel anti-CMV compound AIC246","volume":"11","author":"Kaul","year":"2011","journal-title":"Am J Transplant"},{"key":"10.1016\/j.trre.2016.04.001_bb1310","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1111\/j.1399-0012.2007.00699.x","article-title":"The use of sirolimus in ganciclovir-resistant cytomegalovirus infections in renal transplant recipients","volume":"21","author":"Ozaki","year":"2007","journal-title":"Clin Transpl"},{"key":"10.1016\/j.trre.2016.04.001_bb1315","doi-asserted-by":"crossref","first-page":"e78","DOI":"10.1111\/j.1432-2277.2012.01489.x","article-title":"Successful outcome of ganciclovir-resistant cytomegalovirus infection in organ transplant recipients after conversion to mTOR inhibitors","volume":"25","author":"Sabe","year":"2012","journal-title":"Transpl Int"},{"key":"10.1016\/j.trre.2016.04.001_bb1320","doi-asserted-by":"crossref","first-page":"2655","DOI":"10.1111\/ajt.13327","article-title":"Reduced incidence of cytomegalovirus infection in kidney transplant recipients receiving everolimus and reduced tacrolimus doses","volume":"15","author":"Tedesco-Silva","year":"2015","journal-title":"Am J Transplant"},{"key":"10.1016\/j.trre.2016.04.001_bb1325","doi-asserted-by":"crossref","first-page":"60","DOI":"10.12659\/AOT.884035","article-title":"Leflunomide as a rescue treatment in ganciclovir-resistant cytomegalovirus infection in a seronegative renal transplant recipient \u2014 a case report","volume":"19","author":"Ciszek","year":"2014","journal-title":"Ann Transplant"},{"key":"10.1016\/j.trre.2016.04.001_bb1330","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1111\/j.1399-3062.2011.00682.x","article-title":"Leflunomide for cytomegalovirus: bench to bedside","volume":"14","author":"Chacko","year":"2012","journal-title":"Transpl Infect Dis"},{"key":"10.1016\/j.trre.2016.04.001_bb1335","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1093\/cid\/ciq050","article-title":"Artesunate is ineffective in controlling valganciclovir-resistant cytomegalovirus infection","volume":"52","author":"Lau","year":"2011","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.trre.2016.04.001_bb1340","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.antiviral.2013.10.014","article-title":"Success and failure of artesunate treatment in five transplant recipients with disease caused by drug-resistant cytomegalovirus","volume":"101","author":"Germi","year":"2014","journal-title":"Antiviral Res"},{"key":"10.1016\/j.trre.2016.04.001_bb1345","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1517\/14712598.2014.908847","article-title":"Therapeutic strategies for cytomegalovirus infection in haematopoietic transplant recipients: a focused update","volume":"14","author":"Sellar","year":"2014","journal-title":"Expert Opin Biol Ther"},{"key":"10.1016\/j.trre.2016.04.001_bb1350","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1517\/14712590902967588","article-title":"Adoptive T cell immunotherapy for cytomegalovirus","volume":"9","author":"Peggs","year":"2009","journal-title":"Expert Opin Biol Ther"},{"key":"10.1016\/j.trre.2016.04.001_bb1355","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1111\/ajt.13023","article-title":"Adoptive T cell immunotherapy for treatment of ganciclovir-resistant cytomegalovirus disease in a renal transplant recipient","volume":"15","author":"Macesic","year":"2015","journal-title":"Am J Transplant"},{"key":"10.1016\/j.trre.2016.04.001_bb1360","doi-asserted-by":"crossref","first-page":"3830","DOI":"10.1182\/blood.V99.10.3830","article-title":"Sensitive detection of human cytomegalovirus peptide-specific cytotoxic T-lymphocyte responses by interferon-gamma-enzyme-linked immunospot assay and flow cytometry in healthy individuals and in patients after allogeneic stem cell transplantation","volume":"99","author":"Hebart","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.trre.2016.04.001_bb1365","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1182\/blood.V98.5.1358","article-title":"Tetramer-based quantification of cytomegalovirus (CMV)-specific CD8+ T lymphocytes in T-cell-depleted stem cell grafts and after transplantation may identify patients at risk for progressive CMV infection","volume":"98","author":"Gratama","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.trre.2016.04.001_bb1370","doi-asserted-by":"crossref","first-page":"4360","DOI":"10.1182\/blood-2010-01-262089","article-title":"Adoptive transfer of pp65-specific T cells for the treatment of chemorefractory cytomegalovirus disease or reactivation after haploidentical and matched unrelated stem cell transplantation","volume":"116","author":"Feuchtinger","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.trre.2016.04.001_bb1375","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1055\/s-0033-1333749","article-title":"Adoptive T-cell transfer for refractory viral infections with cytomegalovirus, Epstein\u2013Barr virus or adenovirus after allogeneic stem cell transplantation","volume":"225","author":"Feucht","year":"2013","journal-title":"Klin Padiatr"},{"key":"10.1016\/j.trre.2016.04.001_bb1380","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1046\/j.1365-2141.2001.03106.x","article-title":"Purification of cytomegalovirus-specific CD8 T cells from peripheral blood using HLA-peptide tetramers","volume":"115","author":"Keenan","year":"2001","journal-title":"Br J Haematol"},{"key":"10.1016\/j.trre.2016.04.001_bb1385","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.jim.2007.01.001","article-title":"Reversible HLA multimers (Streptamers) for the isolation of human cytotoxic T lymphocytes functionally active against tumor- and virus-derived antigens","volume":"320","author":"Neudorfer","year":"2007","journal-title":"J Immunol Methods"},{"key":"10.1016\/j.trre.2016.04.001_bb1390","doi-asserted-by":"crossref","unstructured":"M. Assenmacher, M. Lohning, A. Radbruch, Detection and isolation of cytokine secreting cells using the cytometric cytokine secretion assay, Curr Protoc Immunol, Chapter 6 (2002) [Unit 6] 27.","DOI":"10.1002\/0471142735.im0627s46"},{"key":"10.1016\/j.trre.2016.04.001_bb1395","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1111\/j.1600-6143.2009.02672.x","article-title":"Adoptive T-cell therapy of a lung transplanted patient with severe CMV disease and resistance to antiviral therapy","volume":"9","author":"Brestrich","year":"2009","journal-title":"Am J Transplant"},{"key":"10.1016\/j.trre.2016.04.001_bb1400","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1182\/blood-2006-12-063008","article-title":"Allogeneic cytotoxic T-cell therapy for EBV-positive posttransplantation lymphoproliferative disease: results of a phase 2 multicenter clinical trial","volume":"110","author":"Haque","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.trre.2016.04.001_bb1405","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1097\/TP.0b013e3181ffffd3","article-title":"24weeks of valganciclovir prophylaxis in children after renal transplantation: a 4-year experience","volume":"91","author":"Camacho-Gonzalez","year":"2011","journal-title":"Transplantation"},{"key":"10.1016\/j.trre.2016.04.001_bb1410","doi-asserted-by":"crossref","first-page":"1906","DOI":"10.1111\/j.1600-6143.2006.01394.x","article-title":"CMV-IVIG for prevention of Epstein Barr virus disease and posttransplant lymphoproliferative disease in pediatric liver transplant recipients","volume":"6","author":"Green","year":"2006","journal-title":"Am J Transplant"},{"key":"10.1016\/j.trre.2016.04.001_bb1415","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1097\/TP.0b013e3181a492e8","article-title":"The risk, prevention, and outcome of cytomegalovirus after pediatric lung transplantation","volume":"87","author":"Danziger-Isakov","year":"2009","journal-title":"Transplantation"},{"key":"10.1016\/j.trre.2016.04.001_bb1420","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1111\/j.1399-3046.2010.01454.x","article-title":"Cytomegalovirus risk, prevention, and management in pediatric solid organ transplantation","volume":"15","author":"Martin","year":"2011","journal-title":"Pediatr Transplant"},{"key":"10.1016\/j.trre.2016.04.001_bb1425","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1111\/j.1432-2277.2009.00907.x","article-title":"CMV infection, diagnosis and antiviral strategies after liver transplantation","volume":"22","author":"Lautenschlager","year":"2009","journal-title":"Transpl Int"},{"key":"10.1016\/j.trre.2016.04.001_bb1430","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1097\/TP.0000000000000888","article-title":"Cytomegalovirus infection in pediatric renal transplantation and the impact of chemoprophylaxis with (Val-)ganciclovir","volume":"100","author":"Hocker","year":"2015","journal-title":"Transplantation"},{"key":"10.1016\/j.trre.2016.04.001_bb1435","doi-asserted-by":"crossref","first-page":"1798","DOI":"10.1161\/CIRCULATIONAHA.106.627570","article-title":"Positive pretransplantation cytomegalovirus serology is a risk factor for cardiac allograft vasculopathy in children","volume":"115","author":"Hussain","year":"2007","journal-title":"Circulation"},{"key":"10.1016\/j.trre.2016.04.001_bb1440","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1111\/j.1399-3046.2012.01741.x","article-title":"Correlation and clinical utility of pp65 antigenemia and quantitative polymerase chain reaction assays for detection of cytomegalovirus in pediatric renal transplant patients","volume":"16","author":"Rha","year":"2012","journal-title":"Pediatr Transplant"},{"key":"10.1016\/j.trre.2016.04.001_bb1445","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1002\/eji.201243100","article-title":"Cytomegalovirus-specific T cells are detectable in early childhood and allow assignment of the infection status in children with passive maternal antibodies","volume":"43","author":"Ritter","year":"2013","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.trre.2016.04.001_bb1450","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1111\/j.1399-3046.2011.01637.x","article-title":"Cellular immunity to CMV: advancing to the next level","volume":"16","author":"Kumar","year":"2012","journal-title":"Pediatr Transplant"},{"key":"10.1016\/j.trre.2016.04.001_bb1455","doi-asserted-by":"crossref","first-page":"1908","DOI":"10.1111\/ajt.12755","article-title":"Current prevention strategies against cytomegalovirus in the studies in pediatric liver transplantation (SPLIT) centers","volume":"14","author":"Danziger-Isakov","year":"2014","journal-title":"Am J Transplant"},{"key":"10.1016\/j.trre.2016.04.001_bb1460","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1046\/j.1397-3142.2003.00102.x","article-title":"Variability in standard care for cytomegalovirus prevention and detection in pediatric lung transplantation: survey of eight pediatric lung transplant programs","volume":"7","author":"Danziger-Isakov","year":"2003","journal-title":"Pediatr Transplant"},{"key":"10.1016\/j.trre.2016.04.001_bb1465","first-page":"7","article-title":"Cytomegalovirus and paediatric renal transplants: is this a current issue?","volume":"33","author":"Fijo-Lopez-Viota","year":"2013","journal-title":"Nefrologia"},{"key":"10.1016\/j.trre.2016.04.001_bb1470","doi-asserted-by":"crossref","first-page":"246","DOI":"10.5414\/CNP61246","article-title":"Preemptive treatment with oral ganciclovir for pediatric renal transplantation","volume":"61","author":"Melgosa Hijosa","year":"2004","journal-title":"Clin Nephrol"},{"key":"10.1016\/j.trre.2016.04.001_bb1475","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1097\/TP.0b013e31817889e4","article-title":"Prophylaxis followed by preemptive therapy versus preemptive therapy for prevention of human cytomegalovirus disease in pediatric patients undergoing liver transplantation","volume":"86","author":"Gerna","year":"2008","journal-title":"Transplantation"},{"key":"10.1016\/j.trre.2016.04.001_bb1480","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1111\/j.1399-3046.2007.00799.x","article-title":"Prevention of CMV disease in pediatric kidney transplant recipients: evaluation of pp67 NASBA-based pre-emptive ganciclovir therapy combined with CMV hyperimmune globulin prophylaxis in high-risk patients","volume":"12","author":"Renoult","year":"2008","journal-title":"Pediatr Transplant"},{"key":"10.1016\/j.trre.2016.04.001_bb1485","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1097\/TP.0b013e3181a19cda","article-title":"A hybrid strategy for the prevention of cytomegalovirus-related complications in pediatric liver transplantation recipients","volume":"87","author":"Madan","year":"2009","journal-title":"Transplantation"},{"key":"10.1016\/j.trre.2016.04.001_bb1490","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1097\/TP.0b013e31822d873d","article-title":"A universal preemptive therapy for cytomegalovirus infections in children after live-donor liver transplantation","volume":"92","author":"Saitoh","year":"2011","journal-title":"Transplantation"},{"key":"10.1016\/j.trre.2016.04.001_bb1495","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1111\/j.1399-3046.2006.00626.x","article-title":"Safety and efficacy of prolonged cytomegalovirus prophylaxis with intravenous ganciclovir in pediatric and young adult lung transplant recipients","volume":"11","author":"Spivey","year":"2007","journal-title":"Pediatr Transplant"},{"key":"10.1016\/j.trre.2016.04.001_bb1500","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1002\/lt.22471","article-title":"Retrospective review of the incidence of cytomegalovirus infection and disease after liver transplantation in pediatric patients: comparison of prophylactic oral ganciclovir and oral valganciclovir","volume":"18","author":"Bedel","year":"2012","journal-title":"Liver Transpl"},{"key":"10.1016\/j.trre.2016.04.001_bb1505","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1111\/j.1600-6143.2008.02528.x","article-title":"Valganciclovir dosing according to body surface area and renal function in pediatric solid organ transplant recipients","volume":"9","author":"Vaudry","year":"2009","journal-title":"Am J Transplant"},{"key":"10.1016\/j.trre.2016.04.001_bb1510","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1111\/j.1399-3046.2010.01330.x","article-title":"The efficacy and safety of valganciclovir vs. oral ganciclovir in the prevention of symptomatic CMV infection in children after solid organ transplantation","volume":"14","author":"Lapidus-Krol","year":"2010","journal-title":"Pediatr Transplant"},{"key":"10.1016\/j.trre.2016.04.001_bb1515","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1016\/j.transproceed.2009.02.053","article-title":"Impact of valganciclovir on Epstein\u2013Barr virus polymerase chain reaction in pediatric liver transplantation: preliminary report","volume":"41","author":"Venturi","year":"2009","journal-title":"Transplant Proc"},{"key":"10.1016\/j.trre.2016.04.001_bb1520","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1111\/j.1399-3046.2006.00669.x","article-title":"Unexpectedly high inter- and intrapatient variability of ganciclovir levels in children","volume":"11","author":"Vethamuthu","year":"2007","journal-title":"Pediatr Transplant"},{"key":"10.1016\/j.trre.2016.04.001_bb1525","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1111\/petr.12030","article-title":"Valganciclovir dosing using area under the curve calculations in pediatric solid organ transplant recipients","volume":"17","author":"Villeneuve","year":"2013","journal-title":"Pediatr Transplant"},{"key":"10.1016\/j.trre.2016.04.001_bb1530","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1111\/petr.12179","article-title":"New algorithm for valganciclovir dosing in pediatric solid organ transplant recipients","volume":"18","author":"Asberg","year":"2014","journal-title":"Pediatr Transplant"},{"key":"10.1016\/j.trre.2016.04.001_bb1535","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.jcv.2010.01.009","article-title":"Incidence and characterization of cytomegalovirus resistance mutations among pediatric solid organ transplant patients who received valganciclovir prophylaxis","volume":"47","author":"Martin","year":"2010","journal-title":"J Clin Virol"},{"key":"10.1016\/j.trre.2016.04.001_bb1540","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1111\/ajt.13649","article-title":"Impact of everolimus and low-dose cyclosporin on cytomegalovirus replication and disease in pediatric renal transplantation","volume":"16","author":"Hocker","year":"2016","journal-title":"Am J Transplant"},{"key":"10.1016\/j.trre.2016.04.001_bb1545","doi-asserted-by":"crossref","first-page":"2172","DOI":"10.1111\/j.1600-6143.2012.04076.x","article-title":"Prospective analysis of human cytomegalovirus DNAemia and specific CD8+ T cell responses in lung transplant recipients","volume":"12","author":"Weseslindtner","year":"2012","journal-title":"Am J Transplant"},{"key":"10.1016\/j.trre.2016.04.001_bb1550","doi-asserted-by":"crossref","first-page":"2726","DOI":"10.1128\/AAC.05983-11","article-title":"First pharmacokinetic and safety study in humans of the novel lipid antiviral conjugate CMX001, a broad-spectrum oral drug active against double-stranded DNA viruses","volume":"56","author":"Painter","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.trre.2016.04.001_bb1555","doi-asserted-by":"crossref","first-page":"2381","DOI":"10.1128\/AAC.46.8.2381-2386.2002","article-title":"Alkoxyalkyl esters of cidofovir and cyclic cidofovir exhibit multiple-log enhancement of antiviral activity against cytomegalovirus and herpesvirus replication in vitro","volume":"46","author":"Beadle","year":"2002","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.trre.2016.04.001_bb1560","doi-asserted-by":"crossref","first-page":"3321","DOI":"10.1128\/AAC.00062-13","article-title":"Selection and recombinant phenotyping of a novel CMX001 and cidofovir resistance mutation in human cytomegalovirus","volume":"57","author":"James","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.trre.2016.04.001_bb1565","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1128\/AAC.01596-09","article-title":"In vitro and in vivo activities of the novel anticytomegalovirus compound AIC246","volume":"54","author":"Lischka","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.trre.2016.04.001_bb1570","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.antiviral.2015.01.006","article-title":"Phenotypic characterization of two naturally occurring human cytomegalovirus sequence polymorphisms located in a distinct region of ORF UL56 known to be involved in in vitro resistance to letermovir","volume":"116","author":"Goldner","year":"2015","journal-title":"Antiviral Res"},{"key":"10.1016\/j.trre.2016.04.001_bb1575","doi-asserted-by":"crossref","first-page":"10884","DOI":"10.1128\/JVI.05265-11","article-title":"The novel anticytomegalovirus compound AIC246 (letermovir) inhibits human cytomegalovirus replication through a specific antiviral mechanism that involves the viral terminase","volume":"85","author":"Goldner","year":"2011","journal-title":"J Virol"},{"key":"10.1016\/j.trre.2016.04.001_bb1580","doi-asserted-by":"crossref","first-page":"2365","DOI":"10.1128\/AAC.46.8.2365-2372.2002","article-title":"Potent and selective inhibition of human cytomegalovirus replication by 1263W94, a benzimidazole l-riboside with a unique mode of action","volume":"46","author":"Biron","year":"2002","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.trre.2016.04.001_bb1585","doi-asserted-by":"crossref","first-page":"2324","DOI":"10.1111\/j.1600-6143.2009.02768.x","article-title":"A randomized, double-blind, pharmacokinetic study of oral maribavir with tacrolimus in stable renal transplant recipients","volume":"9","author":"Pescovitz","year":"2009","journal-title":"Am J Transplant"},{"key":"10.1016\/j.trre.2016.04.001_bb1590","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1128\/AAC.50.4.1130-1135.2006","article-title":"Maribavir pharmacokinetics and the effects of multiple-dose maribavir on cytochrome P450 (CYP) 1A2, CYP 2C9, CYP 2C19, CYP 2D6, CYP 3a, N-acetyltransferase-2, and xanthine oxidase activities in healthy adults","volume":"50","author":"Ma","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.trre.2016.04.001_bb1595","series-title":"Brincidofovir (CMX001) experience in renal transplant patients for treatment of refractory CMV infection (abstract D2364), American Transplant Congress; San Francisco, USA","author":"F.","year":"2014"},{"key":"10.1016\/j.trre.2016.04.001_bb1600","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1111\/tri.12225","article-title":"Preemptive treatment of cytomegalovirus infection in kidney transplant recipients with letermovir: results of a phase 2a study","volume":"27","author":"Stoelben","year":"2014","journal-title":"Transpl Int"},{"key":"10.1016\/j.trre.2016.04.001_bb1605","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1086\/653122","article-title":"Virologic characterization of multidrug-resistant cytomegalovirus infection in 2 transplant recipients treated with maribavir","volume":"202","author":"Strasfeld","year":"2010","journal-title":"J Infect Dis"}],"container-title":["Transplantation Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0955470X16300040?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0955470X16300040?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,6,19]],"date-time":"2022-06-19T11:28:33Z","timestamp":1655638113000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0955470X16300040"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,7]]},"references-count":321,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2016,7]]}},"alternative-id":["S0955470X16300040"],"URL":"https:\/\/doi.org\/10.1016\/j.trre.2016.04.001","relation":{},"ISSN":["0955-470X"],"issn-type":[{"value":"0955-470X","type":"print"}],"subject":[],"published":{"date-parts":[[2016,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Management of cytomegalovirus infection in solid organ transplant recipients: SET\/GESITRA-SEIMC\/REIPI recommendations","name":"articletitle","label":"Article Title"},{"value":"Transplantation Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.trre.2016.04.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}